<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0402256803
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        COPSFIN 50MG VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CASPOFUNGIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        518.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gland Pharma Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gland Pharma Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AX04 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Caspofungin acetate Injection contains a medicine called caspofungin. This belongs to a group of medicine called anti-fungals.</p><p>What Caspofungin acetate Injection is used for</p><p>Caspofungin acetate Injection is used to treat the following infections in children, adolescents and adults:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; serious fungal infections in your tissues or organs (called &#39;invasive candidiasis&#39;). This infection is caused by fungal (yeast) cells called <em>Candida</em>.</p><p>People who might get this type of infection include those who have just had an operation or those whose immune systems are weak. Fever and chills that do not respond to an antibiotic are the most common signs of this type of infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; fungal infection in your nose, nasal sinuses or lungs (called &lsquo;invasive aspergillosis&rsquo;) if other anti- fungal treatments have not worked or have caused side effects. This infection is caused by a mould called Aspergillus.</p><p>People who might get this type of infection include those having chemotherapy, those who have has a transplant and those whose immune systems are weak.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; suspected fungal infections if you have a fever and a low white cell count that have not improved on treatment with an antibiotic. People who are at risk of getting a fungal infection include those who have had an operation or those whose immune systems are weak.</p><p>&nbsp;</p><p>How Caspofungin acetate Injection works</p><p>Caspofungin acetate Injection makes fungal cells fragile and stops the fungus from growing properly. This stops the infection from spreading and gives the body&rsquo;s natural defences a chance to completely get rid of the infectio</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Caspofungin acetate Injection:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to caspofungin or any of the other ingredients of this medicine (listed in section 6).</p><p>If you are not sure, talk to your doctor, nurse or pharmacist before you are given your medicine.</p><p>Warnings and Precautions</p><p>Talk to your doctor, nurse or pharmacist before you are given Caspofungin acetate Injection if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to any other medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had liver problems - you might need a different dose of this medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; you are already taking cyclosporin (used to help prevent organ transplant rejection or to suppress your immune system) - as your doctor may need to run extra blood tests during your treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had any other medical problem</p><p>If any of the above applies to you (or you are not sure), talk to your doctor, nurse or pharmacist before you are given Caspofungin acetate for Injection.</p><p>Caspofungin acetate Injection may also cause Serious Cutaneous Adverse Reactions such as Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).</p><p>Other medicines and Caspofungin acetate Injection</p><p>Please tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, including herbal medicines. This is because Caspofungin acetate Injection can affect the way some other medicines work. Also, some other medicines can affect the way Caspofungin acetate Injection works.</p><p>Tell your doctor, nurse or pharmacist if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporin or tacrolimus (used to help prevent organ transplant rejection or to suppress your immune system) as your doctor may need to run extra blood tests during your treatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some HIV medicines such as efavirenz or nevirapine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin or carbamazepine (used for the treatment of seizures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dexamethasone (a steroid)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (an antibiotic).</p><p>If any of the above apply to you (or you are not sure), talk to your doctor, nurse or pharmacist before you are given Caspofungin acetate Injection.</p><p>Pregnancy and breast-feeding</p><p>Ask your doctor for advice before taking any medicine, if you are pregnant or breast-feeding or think you are pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caspofungin acetate Injection has not been studied in pregnant women. It should be used in pregnancy only if the potential benefit justifies the potential risk to the unborn baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Women given Caspofungin acetate Injection should not breast-feed.</p><p>&nbsp;</p><p>Driving and using machines</p><p>There is no information to suggest that Caspofungin acetate Injection affects your ability to drive or operate machinery.</p><p>Caspofungin acetate Injection contains sucrose</p><p>&nbsp;</p><p>Caspofungin acetate Injection contains sucrose (a type of sugar). If you have been told by your doctor that you cannot tolerate or digest some sugars, talk to your doctor, nurse or pharmacist before you are given this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Caspofungin acetate Injection will always be prepared and given to you by a healthcare professional.</p><p>You will be given Caspofungin acetate Injection:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; once each day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; by slow injection into a vein (intravenous infusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; over about 1 hour</p><p>Your doctor will determine the duration of your treatment and how much Caspofungin acetate Injection you will be given each day. Your doctor will monitor how well the medicine works for you. If you weigh more than 80 kg, you may need a different dose.</p><p>Children and adolescents</p><p>The dose for children and adolescents may differ from the adult dose.</p><p>If you have been given more Caspofungin acetate Injection than you should</p><p>Your doctor will decide how much Caspofungin acetate Injection you need and for how long each day. If you are worried that you may have been given too much Caspofungin acetate for Injection, tell your doctor or nurse straight away.</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor or nurse straight away if you notice any of the following side effects &ndash; you may need urgent medical treatment:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; rash, itching, feeling warm, swelling of your face, lips or throat or difficulty breathing - you may be having a histamine reaction to the medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing with wheezing or a rash that gets worse - you may be having an allergic reaction to the medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; cough, serious breathing difficulties - if you are an adult and have invasive aspergillosis you may be experiencing a serious respiratory problem that could result in respiratory failure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; rash, skin peeling, mucous membrane sores, hives, large areas of peeling skin.</p><p>As with any prescription medicine, some side effects may be serious. Ask your doctor for more information.</p><p>Other side effects in adults include</p><p><strong>Common: </strong>may affect up to 1 in 10 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Decreased haemoglobin (decreased oxygen carrying substance in the blood), decreased white blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Decreased blood albumin (a type of protein) in your blood, decreased potassium or low potassium levels in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the vein</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, nausea or vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Changes in some laboratory blood tests (including increased values of some liver tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Itching, rash, skin redness or sweating more than usual</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Chills, fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Itching at the injection site.</p><p><strong>Uncommon: </strong>may affect up to 1 in 100 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Changes in some laboratory blood tests (including disease of blood clotting, platelets, red blood cells and white blood cells)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite, increase in amount of body fluid, imbalance of salt in the body, high sugar level in the blood, low calcium level in the blood, increase calcium level in the blood, low magnesium level in the blood, increase in acid level in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Disorientation, feeling nervous, being unable to sleep</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy, decreased feeling or sensitivity (especially in the skin), shaking, feeling sleepy, change in the way things taste, tingling or numbness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision, increase in tears, swollen eyelid, yellowing of the whites of the eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Sensation of fast or irregular heartbeats, rapid heartbeat, irregular heartbeat, abnormal heart rhythm, heart failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Flushing, hot flush, high blood pressure, low blood pressure, redness along a vein which is extremely tender when touched</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Tightening of the bands of muscle around the airways resulting in wheezing or coughing, fast breathing rate, shortness of breath that wakes you up, shortage of oxygen in the blood, abnormal breath sounds, crackling sounds in the lungs, wheezing, nasal congestion, cough, throat pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Belly pain, upper belly pain, bloating, constipation, difficulty swallowing, dry mouth, indigestion, passing gas, stomach discomfort, swelling due to build-up of fluid around the belly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Decreased flow of bile, enlarged liver, yellowing of the skin and/or whites of the eyes, liver injury caused by a drug or chemical, liver disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal skin tissue, generalised itching, hives, rash of varying appearance, abnormal skin, red often itchy spots on your arms and legs and sometimes on the face and the rest of the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Back pain, pain in an arm or leg, bone pain, muscle pain, muscle weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Loss of kidney function, sudden loss of kidney function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Catheter site pain, injection site complaints (redness, hard lump, pain, swelling, irritation, rash, hives, leaking of fluid from the catheter into the tissue), inflammation of vein at injection site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood pressure and alterations in some laboratory blood tests (including kidney electrolyte and clotting tests), increased levels of the medicines you are taking that weaken the immune system</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Chest discomfort, chest pain, feeling of body temperature change, generally feeling unwell, general pain, swelling of the face, swelling of the ankles, hands or feet, swelling, tenderness, feeling tired.</p><p>Side effects in children and adolescents</p><p><strong>Very common: </strong>may affect more than 1 in 10 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p><strong>Common: </strong>may affect up to 1 in 10 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fast heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Flushing, low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Changes in some laboratory blood tests (increased values of some liver tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Itching, rash</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Catheter site pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Changes in some laboratory blood tests</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and the vial (the first two numbers are the month; the next four numbers are the year). The expiry date refers to the last day of that month.</p><p>Store Refrigerated at 2&deg;C &ndash; 8&deg;C.</p><p>Once Caspofungin acetate Injection has been prepared, it should be used straight away. This is because it does not contain any ingredients to stop the growth of bacteria. Only a trained healthcare professional who has read the complete directions should prepare the medicine (please see below &ldquo;Information intended for medical or healthcare professionals&rdquo;).</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The active substance ingredient is Caspofungin <u>Caspofungin acetate for Injection, 50 mg/vial</u></p><p>Each vial of Caspofungin acetate Injection contains 50 mg of caspofungin. <u>Caspofungin acetate for Injection, 70 mg/vial</u></p><p>Each vial of Caspofungin acetate Injection contains 70 mg of caspofungin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are- Mannitol, Sucrose, Glacial acetic acid, Sodium Hydroxide (to adjust the pH)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Caspofungin acetate Injection is sterile, white to off white lyophilized cake/powder for intravenous
(IV) infusion.
The container closure system for Caspofungin acetate Injection is listed below. Caspofungin acetate for Injection, 50 mg/vial
10 mL USP Type-I clear glass tubular Lyo vials with 20 mm ready to sterilize bromobutyl double slotted Lyo rubber stoppers and 20 mm aluminum flip-off seals with button.
Caspofungin acetate for Injection, 70 mg/vial
10 mL USP Type-I clear glass tubular Lyo vials with 20 mm ready to sterilize bromobutyl double slotted Lyo rubber stoppers and 20 mm aluminum flip-off seals with button.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MAH and Secondary packaging:</p><p>Boston Oncology Arabia</p><p>Sudair Industrial City,</p><p>Sudair, Saudi Arabia</p><p>&nbsp;</p><p>Full Manufacturing and Primary Packaging:</p><p>Gland Pharma Limited</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 This leaflet was last revised in 04/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن&nbsp;</strong>على دواء يسمى كاسبوفونجين. وهذا ينتمي إلى مجموعة الأدوية المسماة مضادات الفطريات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لأجل ماذا يُستخدم&nbsp;</strong><strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong></p><p dir="RTL">يستخدم&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن&nbsp;</strong>لمعالجة الالتهابات التالية لدى الأطفال, المراهقين والبالغين:</p><p dir="RTL">&bull; الالتهابات الفطرية الخطيرة في أنسجتك أو أعضائك (تسمى داء المبيضات الغازية). تحدث هذه الالتهابات بسبب خلايا (خميرة) فطرية تسمى&nbsp;<em>المبيضات</em>.&nbsp;الأشخاص الذين قد يصابون بهذا النوع من الالتهاب بما فيهم أولئك الذين أجروا للتو عملية جراحية أو أولئك الذين أجهزتهم المناعية ضعيفة. الحمى والقشعريرة التي لا تستجيب للمضاد الحيوي هي العلامات الأكثر شيوعاً لهذا النوع من الالتهابات.</p><p dir="RTL">&bull; الالتهابات الفطرية في أنفك, جيوبك الأنفية أو الرئتين (وتسمى &quot;الرشاشيات الغازية&quot;) إذا لم تنجح العلاجات الأخرى المضادة للفطريات أو تسببت في تأثيرات جانبية. تحدث هذه الالتهابات بسبب تعفُّن يسمى الرشاشية.&nbsp;الأشخاص الذين قد يصابون بهذا النوع من الالتهابات بما فيهم أولئك الذين يتلقون العلاج الكيميائي، وأولئك الذين لديهم عملية زرع وأولئك الذين أجهزة المناعة لديهم ضعيفة.</p><p dir="RTL">&bull; الالتهابات الفطرية المشتبه بها إذا كان عندك حمى وانخفاض عدد الخلايا البيضاء التي لم تتحسن بالعلاج بمضاد حيوي. يشمل الأشخاص المعرضون لخطر الإصابة بالالتهابات الفطرية أولئك الذين أجروا عملية جراحية أو أولئك الذين أجهزتهم المناعية ضعيفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل&nbsp;</strong><strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong></p><p dir="RTL">يجعل&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong>&nbsp;الخلايا الفطرية هشة ويوقف نمو الفطريات بشكل صحيح. وهذا يوقف انتشار الالتهاب ويُعطي دفاعات الجسم الطبيعية فرصة كاملة للتخلص من الالتهاب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم&nbsp;</strong><strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن:</strong></p><p dir="RTL">&bull; إذا كنت تعاني من حساسية تجاه كاسبوفونجين أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">إذا لم تكن متأكداً، تحدث إلى طبيبك, الممرضة أو الصيدلي قبل أن تُعطى دواءك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك, ممرضتك أو الصيدلي قبل أن تُعطى&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong>&nbsp;إذا:</p><p dir="RTL">&bull; كنت تتحسس من أية أدوية أخرى.</p><p dir="RTL">&bull; عانيت في الماضي من مشاكل في الكبد - قد تحتاج إلى جرعة مختلفة من هذا الدواء.</p><p dir="RTL">&bull; كنت تتناول بالفعل سايكلوسبورين (المستخدم للمساعدة في منع رفض زرع الأعضاء أو قمع جهاز المناعة) - حيث قد يحتاج طبيبك إلى إجراء اختبارات دم إضافية أثناء العلاج.</p><p dir="RTL">&bull; إذا كان لديك أية مشكلة طبية أخرى.</p><p dir="RTL">إذا كان أيّ مما سبق ينطبق عليك (أو كنت غير متأكد)، تحدث إلى طبيبك, ممرضتك أو الصيدلي قبل أن تُعطى&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>للحقن</strong>.</p><p dir="RTL">قد يسبب&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong>&nbsp;أيضاً ردود فعل جلدية خطيرة مثل متلازمة ستيفنز- جونسون (SJS) وانحلال البشرة السمي (TEN).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى و</strong><strong>&nbsp;كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong></p><p dir="RTL">يرجى إخبار طبيبك, ممرضتك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخراً أو قد تتناول أية أدوية أخرى. يشمل ذلك الأدوية التي تحصل عليها بدون وصفة طبية، بما في ذلك الأدوية العشبية. هذا لأن&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن&nbsp;</strong>يمكن أن يؤثر على طريقة عمل بعض الأدوية الأخرى. ويمكن أيضاً أن تؤثر بعض الأدوية الأخرى على طريقة عمل&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong>.</p><p dir="RTL">أخبر طبيبك, ممرضتك أو الصيدلي إذا كنت تتناول أيّاً من الأدوية التالية:</p><p dir="RTL">&bull; سايكلوسبورين أو تاكروليموس (المستخدمة للمساعدة في منع رفض زرع الأعضاء أو قمع جهاز المناعة) حيث قد يحتاج طبيبك إلى إجراء اختبارات دم إضافية أثناء العلاج.</p><p dir="RTL">&bull; بعض أدوية فيروس نقص المناعة البشرية مثل إفافيرنز أو نيفيرابين.</p><p dir="RTL">&bull; فينيتوئين أو كاربامازيبين (المستخدمة لعلاج النوبات).</p><p dir="RTL">&bull; ديكساميثازون (ستيرويد).</p><p dir="RTL">&bull; ريفامبيسين (مضاد حيوي).</p><p dir="RTL">إذا كان أيّ مما سبق ينطبق عليك (أو كنت غير متأكد)، تحدث إلى طبيبك, ممرضتك أو الصيدلي قبل أن تُعطى&nbsp;<strong>كاسبوفونجين أسيتات ل</strong><strong>لحقن</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">اطلبي نصيحة طبيبكِ قبل تناول أي دواء، إذا كنتِ حاملاً أو مرضعةً أو تظنين أنكِ حاملاً.</p><p dir="RTL">&bull; لم تتم دراسة&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن&nbsp;</strong>لدى النساء الحوامل. يجب استخدامه أثناء الحمل فقط إذا كانت الفائدة المرجوة تبرر المخاطر المحتملة على الجنين.</p><p dir="RTL">&bull; يجب على النساء اللواتي يُعطى لهن&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong>&nbsp;عدم الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا توجد معلومات تشير إلى أن&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong>&nbsp;قد يؤثر على قدرتك في القيادة أو تشغيل الآلات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي&nbsp;</strong><strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن على السكروز.</strong></p><p dir="RTL">يحتوي&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong>&nbsp;على السكروز (نوع من السكر). إذا أخبرك طبيبك أنه لا يمكنك تحمُّل أو هضم بعض السكريات، تحدث إلى طبيبك, ممرضتك أو الصيدلي قبل أن تُعطى هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم تحضير وإعطاء&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong>&nbsp;لك دائماً من قبل أخصائي الرعاية الصحية.</p><p dir="RTL">سوف تُعطى&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong>:</p><p dir="RTL">&bull; مرة كل يوم.</p><p dir="RTL">&bull; عن طريق الحقن البطيء داخل الوريد (التسريب في الوريد).</p><p dir="RTL">&bull; في مدة ساعة واحدة.</p><p dir="RTL">سيحدد طبيبك مدة العلاج وكمية&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong>&nbsp;&nbsp;التي ستُعطى لك كل يوم. سيراقب طبيبك مدى فاعلية الدواء لديك. إذا كنت تزن أكثر من 80 كغ، فقد تحتاج إلى جرعة مختلفة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">قد تختلف جرعة الأطفال والمراهقين عن جرعة البالغين.</p><p dir="RTL"><strong>إذا أُعطيت&nbsp;</strong><strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن أكثر مما يجب</strong></p><p dir="RTL">سيقرر طبيبك كمية&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong>&nbsp;التي تحتاجها كل يوم والمدة اللازمة. إذا كنت قلقاً من أنك قد أُعطيت الكثير من&nbsp;<strong>كاسبوفونجين أسيتات</strong><strong>&nbsp;للحقن</strong>، أخبر طبيبك أو الممرضة على الفور.</p><p dir="RTL"><strong>إذا كان لديك أية أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك, ممرضتك أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء تأثيرات جانبية، وإن كانت لا تحدث لكل شخص.</p><p dir="RTL"><strong>أخبر طبيبك أو الممرضة على الفور إذا لاحظت أيّاً من التأثيرات الجانبية التالية - فقد تحتاج إلى معالجة طبية عاجلة:</strong></p><p dir="RTL">&bull; طفح جلدي، حكة، شعور بالدفء، تورم في الوجه، الشفتين أو الحلق أو صعوبة في التنفس - وقد تتصرف برد فعل هيستاميني تجاه الدواء.</p><p dir="RTL">&bull; صعوبة التنفس مع صفير أو طفح جلدي يزداد سوءاً - فقد يكون لديك رد فعل تحسسي تجاه الدواء.</p><p dir="RTL">&bull; سعال، صعوبات خطيرة في التنفس - إذا كنت كبير السن ولديك داء الرشاشيات الغازية، فقد تعاني من مشكلة تنفسية خطيرة قد تؤدي إلى فشل تنفسي.</p><p dir="RTL">&bull; طفح جلدي، تقشر جلد، تقرحات أغشية مخاطية، بثور, ومساحات واسعة من تقشر الجلد.</p><p dir="RTL">كما هو الحال مع أية وصفة طبية، قد تكون بعض التأثيرات الجانبية خطيرة. اسأل طبيبك لمزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأثيرات جانبية أخرى لدى البالغين تشمل:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة:</strong>&nbsp;قد تؤثر حتى في 1 من كل 10 أشخاص:</p><p dir="RTL">&bull; انخفاض الهيموجلوبين (انخفاض نسبة المادة التي تحمل الأكسجين في الدم)، وانخفاض خلايا الدم البيضاء.</p><p dir="RTL">&bull; انخفاض ألبومين الدم (نوع من البروتين) في الدم، وانخفاض البوتاسيوم أو انخفاض مستويات البوتاسيوم في الدم.</p><p dir="RTL">&bull; صداع الرأس.</p><p dir="RTL">&bull; التهاب الوريد.</p><p dir="RTL">&bull; ضيق في التنفس.</p><p dir="RTL">&bull; إسهال أو غثيان أو قيء.</p><p dir="RTL">&bull; تغيرات في بعض اختبارات الدم المخبرية (بما في ذلك قيم متزايدة لبعض اختبارات الكبد).</p><p dir="RTL">&bull; حكة, طفح جلدي, احمرار الجلد أو التعرق أكثر من المعتاد.</p><p dir="RTL">&bull; ألم المفاصل.</p><p dir="RTL">&bull; قشعريرة، حمى.</p><p dir="RTL">&bull; حكة في موقع الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة:</strong>&nbsp;قد تؤثر حتى في 1 من كل 100 شخص:</p><p dir="RTL">&bull; تغيرات في بعض اختبارات الدم المخبرية (بما في ذلك مرض تخثر الدم, الصفائح الدموية, خلايا الدم الحمراء وخلايا الدم البيضاء).</p><p dir="RTL">&bull; فقدان شهية، زيادة كمية سوائل الجسم، عدم توازن الملح في الجسم، ارتفاع مستوى السكر في الدم، انخفاض مستوى الكالسيوم في الدم، زيادة مستوى الكالسيوم في الدم، انخفاض مستوى المغنيزيوم في الدم، زيادة مستوى الحمض في الدم.</p><p dir="RTL">&bull; ارتباك، شعور بالتوتر، عدم القدرة على النوم.</p><p dir="RTL">&bull; شعور بالدوار، انخفاض في الشعور أو الحساسية (خاصة في الجلد)، ارتعاش، شعور بالنعاس، تغيُّر بطريقة طعم الأشياء، وخز أو خَدَر.</p><p dir="RTL">&bull; رؤية غير واضحة، زيادة الدموع، انتفاخ الجفن، اصفرار بياض العينين.</p><p dir="RTL">&bull; شعور بسرعة أو عدم انتظام ضربات القلب, سرعة ضربات القلب، عدم انتظام ضربات القلب، ضربات قلب غير طبيعية, قصور القلب.</p><p dir="RTL">&bull; تورُّد, توهُّج ساخن, ارتفاع ضغط الدم، انخفاض ضغط الدم، احمرار على طول الوريد الذي يكون حساساً جداً عند لمسه.</p><p dir="RTL">&bull; أربطة عضلات مشدودة حول المسالك الهوائية عند صفير التنفس أو السعال، تنفس سريع نسبياً، ضيق تنفس يدعو لليقظة, نقص أكسجين الدم، أصوات تنفس غير طبيعية، أصوات فرقعة في الرئتين، صفير، احتقان أنف، سعال, و ألم الحلق.</p><p dir="RTL">&bull; ألم بطن، ألم بطن علوي، نفخة، إمساك، صعوبة بلع، جفاف فم، عسر الهضم، تمرير غازات ، إزعاج في المعدة، تورم بسبب تراكم السوائل حول البطن.</p><p dir="RTL">&bull; انخفاض تدفق الصفراء، تضخم الكبد، إصفرار الجلد و/أو بياض العينين، إصابة كبد ناجمة عن دواء أو مادة كيميائية، اضطراب كبد.</p><p dir="RTL">&bull; نسيج جلدي غير طبيعي، حكة عامة، بثور، طفح جلدي متفاوت المظهر, جلد غير طبيعي، بقع حمراء غالباُ ذات حكة على ذراعيك وساقيك وأحياناً على الوجه وبقية أنحاء الجسم.</p><p dir="RTL">&bull; ألم ظهر، ألم في الذراع أو الساق، آلام عظام، آلام عضلات، ضعف عضلات.</p><p dir="RTL">&bull; فقدان وظيفة الكلى، فقدان مفاجئ في وظيفة الكلى.</p><p dir="RTL">&bull; ألم بموقع القسطرة، شكاوَى بموقع الحقن (احمرار، ورم صلب, ألم، تورم، تهيج، طفح جلد، بثور، تسرُّب سوائل من القسطرة إلى الأنسجة)، التهاب الوريد في موقع الحقن.</p><p dir="RTL">&bull; زيادة ضغط الدم وتغيرات في بعض اختبارات الدم المخبرية (بما في ذلك اختبارات الكلى والتخثر)، زيادة مستويات الأدوية التي تتناولها والتي تضعف جهاز المناعة.</p><p dir="RTL">&bull; عدم ارتياح في الصدر، ألم في الصدر، شعور بتغيُّر درجة حرارة الجسم، شعور عام بوعكة صحية، ألم عام، تورم في الوجه، تورم في الكاحلين، اليدين أو القدمين، تورم، ألم ضاغط، شعور بالتعب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثيرات جانبية لدى الأطفال والمراهقين</strong></p><p dir="RTL"><strong>شائعة جداً:</strong>&nbsp;قد تؤثر في أكثر من 1 من كل 10 أشخاص:</p><p dir="RTL">&bull; حمى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة:</strong>&nbsp;قد تؤثر حتى في 1 من كل 10 أشخاص:</p><p dir="RTL">&bull; صداع الرأس.</p><p dir="RTL">&bull; ضربات قلب سريعة.</p><p dir="RTL">&bull; تورُّد، انخفاض ضغط الدم.</p><p dir="RTL">&bull; تغيرات في بعض اختبارات الدم المخبرية (زيادة قيم بعض اختبارات الكبد).</p><p dir="RTL">&bull; حكة, طفح جلدي.</p><p dir="RTL">&bull; ألم بموقع القسطرة.</p><p dir="RTL">&bull; قشعريرة.</p><p dir="RTL">&bull; تغيرات في بعض اختبارات الدم المخبرية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة والقارورة (الرقمان الأولان هما الشهر، والأرقام الأربعة التالية هي السنة). يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">احفظه في البراد بدرجة حرارة 2 إلى 8 مئوية.</p><p dir="RTL">بمجرد تحضير&nbsp;<strong>كاسبوفونجين أسيتات حقن</strong>، ينبغي استخدامه على الفور. هذا لأنه لا يحتوي على أية مكونات لوقف نمو الجراثيم. يجب فقط على أخصائي الرعاية الصحية المدَرَّب الذي قرأ التوجيهات الكاملة أن يقوم بتحضير الدواء(رجاء مراجعة ما يلي &quot;المعلومات المخصصة للعاملين في المجال الطبي أو أخصائي الرعاية الصحية&quot;).</p><p dir="RTL">لا ترمي أية أدوية عن طريق مياه الصرف الصحي أو في حاوية النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير مهمة في المساعدة على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">&bull; المادة الفعالة هي كاسبوفونجين.</p><p dir="RTL"><strong><u>كاسبوفونجين أسيتات حقن</u></strong><u>, 50 ملغ/قارورة</u></p><p dir="RTL">كل قارورة من&nbsp;<strong>كاسبوفونجين أسيتات حقن</strong>&nbsp;تحتوي على 50 ملغ كاسبوفونجين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>كاسبوفونجين أسيتات حقن</u></strong><u>, 70 ملغ/قارورة</u></p><p dir="RTL">كل قارورة من&nbsp;<strong>كاسبوفونجين أسيتات حقن</strong>&nbsp;تحتوي على 70 ملغ كاسبوفونجين.</p><p dir="RTL">&bull; المكونات الأخرى هي - مانيتول، سكروز، حمض الخل الجليدي، هايدروكسايد الصوديوم (لضبط عامل الحموضة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>إن كاسبوفونجين أسيتات حقن&nbsp;</strong>هو كتلة/مسحوق معقم, أبيض إلى أبيض فاتح مجفف معد للحقن الوريدي&nbsp;(IV).</p><p dir="RTL">طريقة إغلاق عبوة&nbsp;<strong>كاسبوفونجين أسيتات حقن</strong>&nbsp;&nbsp;مدرجة أدناه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>كاسبوفونجين أسيتات حقن</u></strong><u>,&nbsp;&nbsp;50 ملغ/قارورة</u></p><p dir="RTL">قوارير&nbsp;Lyo&nbsp;أنبوبية من الزجاج الصافي نوع-1&nbsp;USP&nbsp;سعة 10 مل, مع سدادات مطاطية&nbsp;Lyo&nbsp;20 مم ذات شقين من بروموتيل جاهزة للتعقيم وختم ألمنيوم منقلب 20 مم مزود بزر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>كاسبوفونجين أسيتات حقن</u></strong><u>,&nbsp;&nbsp;70 ملغ/قارورة</u></p><p dir="RTL">قوارير&nbsp;Lyo&nbsp;أنبوبية من الزجاج الصافي نوع-1&nbsp;USP&nbsp;سعة 10 مل, مع سدادات مطاطية&nbsp;Lyo&nbsp;20 مم ذات شقين من بروموتيل جاهزة للتعقيم وختم ألمنيوم منقلب 20 مم مزود بزر.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أ- مالك حقوق التسويق والتغليف الثانوي:</p><p dir="RTL">شركة بوستن انكولجي العربية</p><p dir="RTL">منطقة سدير الصناعية، سدير، المملكة العربية السعودية</p><p dir="RTL">ب- التصنيع الكامل والتغليف الأولي:</p><p dir="RTL">قلاند فارما ليميتيد</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            4/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Caspofungin acetate for Injection 50 mg/vial and 70 mg/vial, 10 mL lyo vial
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Caspofungin acetate for Injection 50 mg/vial,10 mL lyo vial Each vial contains 50 mg caspofungin (as acetate). Caspofungin acetate for Injection and 70 mg/vial, 10 mL lyo vial Each vial contains 70 mg caspofungin (as acetate).
Excipient(s) with known effect:
For a full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Caspofungin acetate for Injection is sterile, white to off white lyophilized cake/powder for intravenous (IV) infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caspofungin acetate for Injection is indicated in adults and pediatric patients (3 months of age and older) for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Empirical therapy for presumed fungal infections in febrile, neutropenic patients.</p><p>&middot;&nbsp;&nbsp;&nbsp; Treatment of candidemia and the following <em>Candida </em>infections: intra-abdominal abscesses, peritonitis and pleural space infections.</p><p>&middot;&nbsp;&nbsp;&nbsp; Treatment of esophageal candidiasis.</p><p>&middot;&nbsp;&nbsp;&nbsp; Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ol><li><p><strong>Important Administration Instructions for Use in All Patients</strong></p><p>Administer Caspofungin acetate for Injection by slow intravenous (IV) infusion over approximately 1 hour. Do not administer Caspofungin acetate for Injection by IV bolus administration.</p>&nbsp;<p><u>Posology</u></p><p>Recommended Dosage in Adult Patients [18 years of age and older]</p><p>The dosage and duration of Caspofungin acetate for Injection treatment for each indication are as follows:</p><p><em>Empirical Therapy for Presumed Fungal Infections in Febrile Neutropenic Patients </em>Administer a single 70-mg loading dose on Day 1, followed by 50 mg once daily thereafter. Duration of treatment should be based on the patient&#39;s clinical response. Continue empirical therapy until resolution of neutropenia. In general, treat patients found to have a fungal infection for a minimum of 14 days after the last positive culture and continue treatment for at least 7 days after both neutropenia and clinical symptoms are resolved. If the 50-mg dose is well tolerated but does not provide an adequate clinical response, the daily dose can be increased to 70 mg.</p><p><em>Candidemia and Other Candida Infections</em></p><p>Administer a single 70-mg loading dose on Day 1, followed by 50 mg once daily thereafter. Duration of treatment should be dictated by the patient&#39;s clinical and microbiological response. In general, continue antifungal therapy for at least 14 days after the last positive culture. Patients with neutropenia who remain persistently neutropenic may warrant a longer course of therapy pending resolution of the neutropenia.</p><p><em>Esophageal Candidiasis</em></p><p>The dose is 50 mg once daily for 7 to 14 days after symptom resolution. A 70-mg loading dose has not been studied for this indication. Because of the risk of relapse of oropharyngeal candidiasis in patients with HIV infections, suppressive oral therapy could be considered.</p><p><em>Invasive Aspergillosis</em></p><p>Administer a single 70-mg loading dose on Day 1, followed by 50 mg once daily thereafter. Duration of treatment should be based upon the severity of the patient&#39;s underlying disease, recovery from immunosuppression, and clinical response.</p><p>Recommended Dosing in Pediatric Patients [3 months to 17 years of age]</p><p>For all indications, administer a single 70 mg/m<sup>2</sup> loading dose on Day 1, followed by 50 mg/m<sup>2</sup> once daily thereafter. The maximum loading dose and the daily maintenance dose should not</p>&nbsp;<p>exceed 70 mg, regardless of the patient&#39;s calculated dose. Dosing in pediatric patients (3 months to 17 years of age) should be based on the patient&#39;s body surface area (BSA) as calculated by the Mosteller Formula.</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image2.jpeg" o:spid="_x0000_s2050" type="#_x0000_t75"
  style='position:absolute;margin-left:90pt;margin-top:7.35pt;width:215.35pt;
  height:42.1pt;z-index:486023168;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/L/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p>&nbsp;</p></td></tr></tbody></table><!--[if gte vml 1]></o:wrapblock><![endif]--><p><img src="data:image/jpeg;base64,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" alt="" width="440" height="96" vspace="0" hspace="0" border="0" style="width:440px;height:96px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Following calculation of the patient&#39;s BSA, the loading dose in milligrams should be calculated as BSA (m<sup>2</sup>) &times; 70 mg/m<sup>2</sup>. The maintenance dose in milligrams should be calculated as BSA (m<sup>2</sup>) &times; 50 mg/m<sup>2</sup>.</p><p>Duration of treatment should be individualized to the indication, as described for each indication in adults. If the 50-mg/m<sup>2</sup> daily dose is well tolerated but does not provide an adequate clinical response, the daily dose can be increased to 70 mg/m<sup>2</sup> daily (not to exceed 70 mg).</p><p>Dosage Adjustments in Patients with Hepatic Impairment</p><p>Adult patients with mild hepatic impairment (Child-Pugh score 5 to 6) do not need a dosage adjustment.</p><p>For adult patients with moderate hepatic impairment (Child-Pugh score 7 to 9), Caspofungin acetate for Injection 35 mg once daily is recommended based upon pharmacokinetic data (see section 5.2) with a 70-mg loading dose administered on Day 1 where appropriate. There is no clinical experience in adult patients with severe hepatic impairment (Child-Pugh score greater than 9) and in pediatric patients with any degree of hepatic impairment.</p><p>Dosage Adjustments in Patients Receiving Concomitant Inducers of Hepatic CYP Enzymes</p><p><u>Adult Patients:</u></p><p>Adult patients on rifampin should receive 70 mg of Caspofungin acetate for Injection once daily. When Caspofungin acetate for Injection is coadministered to adult patients with other inducers of hepatic CYP enzymes such as nevirapine, efavirenz, carbamazepine, dexamethasone, or phenytoin, administration of a daily dose of 70 mg of Caspofungin acetate for Injection should be considered (see section 4.5).</p>&nbsp;<p><u>Pediatric Patients:</u></p><p>Pediatric patients on rifampin should receive 70 mg/m<sup>2</sup> of Caspofungin acetate for Injection daily (not to exceed an actual daily dose of 70 mg). When Caspofungin acetate for Injection is co-administered to pediatric patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, a Caspofungin acetate for Injection dose of 70 mg/m<sup>2</sup> once daily (not to exceed 70 mg) should be considered (see section 4.5).</p></li></ol><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Caspofungin acetate for Injection is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to any component of this product (see section 4.4).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity</u></p><p>Anaphylaxis and other hypersensitivity reactions have been reported during administration of Caspofungin acetate for Injection.</p><p>Possible histamine-mediated adverse reactions, including rash, facial swelling, angioedema, pruritus, sensation of warmth or bronchospasm have been reported.</p><p>Cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), some with a fatal outcome, have been reported with use of Caspofungin acetate for Injection (see section 4.6)</p><p>Discontinue Caspofungin acetate for Injection at the first sign or symptom of a hypersensitivity reaction and administer appropriate treatment.</p><p><u>Hepatic Effects</u></p><p>Laboratory abnormalities in liver function tests have been seen in healthy volunteers and in adult and pediatric patients treated with Caspofungin acetate for Injection. In some adult and pediatric patients with serious underlying conditions who were receiving multiple concomitant medications with Caspofungin acetate for Injection, isolated cases of clinically significant hepatic dysfunction, hepatitis, and hepatic failure have been reported; a causal relationship to Caspofungin acetate for Injection has not been established. Monitor patients who develop abnormal liver function tests during Caspofungin acetate for Injection therapy for evidence of worsening hepatic function and evaluated for risk/benefit of continuing Caspofungin acetate for Injection therapy.</p><p><u>Elevated Liver Enzymes During Concomitant Use with Cyclosporine</u></p><p>Elevated liver enzymes have occurred in patients receiving Caspofungin acetate for Injection and cyclosporine concomitantly. Only use Caspofungin acetate for Injection and cyclosporine in those patients for whom the potential benefit outweighs the potential risk. Patients who develop abnormal liver enzymes during concomitant therapy should be monitored and the risk/benefit of continuing therapy should be evaluated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cyclosporine:&nbsp;In two adult clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of Caspofungin acetate for Injection. Caspofungin acetate for Injection did not increase the plasma levels of cyclosporine.<br />There were transient increases in liver ALT and AST when Caspofungin acetate for Injection and cyclosporine were coadministered. Monitor patients who develop abnormal liver enzymes during concomitant therapy and evaluate the risk/benefit of continuing therapy (see section 4.4 and 5).</p><p>Tacrolimus:&nbsp;For patients receiving Caspofungin acetate for Injection and tacrolimus, standard monitoring of tacrolimus trough whole blood concentrations and appropriate tacrolimus dosage adjustments are recommended.<br />Inducers of Hepatic CYP Enzymes</p><p>Rifampin:&nbsp;Rifampin is a potent CYP3A4 inducer and concomitant administration with Caspofungin acetate for Injection is expected to reduce the plasma concentrations of Caspofungin acetate for Injection. Therefore, adult patients on rifampin<br />should receive 70 mg of Caspofungin acetate for Injection daily and pediatric patients on rifampin should receive 70 mg/m2&nbsp;of Caspofungin acetate for Injection daily (not to exceed an actual daily dose of 70 mg) (see section 4.2 and 5.2).</p><p>Other Inducers of Hepatic CYP Enzymes<br />Adults: When Caspofungin acetate for Injection is co-administered to adult patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily dose of 70 mg of Caspofungin acetate for Injection should be considered (see section 4.2 and 5.2).</p><p>&nbsp;</p><p>Pediatric Patients: When Caspofungin acetate for Injection is co-administered to pediatric patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily dose of 70 mg/m2&nbsp;Caspofungin acetate for Injection (not to exceed an actual daily dose of 70 mg) should be considered (see section 4.2 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no adequate and well-controlled studies with the use of Caspofungin acetate for Injection in pregnant women. In animal studies, caspofungin caused embryofetal toxicity, including increased resorptions, increased peri-implantation loss, and incomplete ossification at multiple fetal sites. Caspofungin acetate for Injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<br />In offspring born to pregnant rats treated with caspofungin at doses comparable to the human dose based on body surface area comparisons, there was incomplete ossification of the skull and torso and increased incidences of cervical rib. There was also an increase in resorptions and peri-implantation losses. In pregnant rabbits treated with caspofungin at dose comparable to 2 times the human dose based on body surface area comparisons, there was an increased incidence of incomplete ossification of the talus/calcaneus in offspring and increases in fetal resorptions. Caspofungin crossed the placenta in rats and rabbits and was detectable in fetal plasma.<br />Nursing Mothers<br />It is not known whether caspofungin is present in human milk. Caspofungin was found in the milk of lactating, drug-treated rats. Because many drugs are excreted in human milk, caution should be exercised when caspofungin is administered to a nursing woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following serious adverse reactions are discussed in detail in another section of the labeling:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity <em>[see Special warnings and precautions for use &ndash; section 4.4]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic Effects <em>[see Special warnings and precautions for use &ndash; section 4.4]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated Liver Enzymes During Concomitant Use with Cyclosporine <em>[see Interaction with other medicinal products and other forms of interaction &ndash; section 4.5]</em></p><p><u>Clinical Trials Experience</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of caspofungin cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice</p><p><u>Adults</u></p><p>The overall safety of Caspofungin acetate for Injection was assessed in 1865 adult individuals who received single or multiple doses of Caspofungin acetate for Injection : 564 febrile, neutropenic patients (empirical therapy study); 382 patients with candidemia and/or intra-abdominal abscesses, peritonitis, or pleural space infections (including 4 patients with chronic disseminated candidiasis); 297 patients with esophageal and/or oropharyngeal candidiasis; 228 patients with invasive aspergillosis; and 394 individuals in phase I studies. In the empirical therapy study patients had undergone hematopoietic stem-cell transplantation or chemotherapy. In the studies involving patients with documented <em>Candida </em>infections, the majority of the patients had serious underlying medical conditions (e.g., hematologic or other malignancy, recent major surgery, HIV) requiring multiple concomitant medications. Patients in the noncomparative Aspergillus studies often had serious predisposing medical conditions (e.g., bone marrow or peripheral stem cell transplants, hematologic malignancy, solid tumors or organ transplants) requiring multiple concomitant medications.</p><p><em>Empirical Therapy for Presumed Fungal Infections in Febrile Neutropenic Patients</em></p><p>In the randomized, double-blinded empirical therapy study, patients received either Caspofungin acetate for Injection 50 mg/day (following a 70-mg loading dose) or AmBisome (amphotericin B liposome for injection, 3 mg/kg/day). In this study clinical or laboratory hepatic adverse reactions were reported in 39% and 45% of patients in the Caspofungin acetate for Injection and AmBisome groups, respectively. Also reported was an isolated, serious adverse reaction of hyperbilirubinemia. Adverse reactions occurring in 7.5% or greater of the patients in either treatment group are presented in Table 1.</p><p>Table 1: Adverse Reactions Among Patients with Persistent Fever and Neutropenia Incidence 7.5% or greater for at Least One Treatment Group</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>Caspofungin acetate</strong></p><p><strong>for Injection* N=564 (percent)</strong></p></td><td style="vertical-align:top"><p><strong>AmBisome<sup>&dagger;</sup> N=547 (percent)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Systems, Any Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>95</strong></p></td><td style="vertical-align:top"><p><strong>97</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><strong>58</strong></p></td><td style="vertical-align:top"><p><strong>63</strong></p></td></tr><tr><td style="vertical-align:top"><p>Alanine Aminotransferase increased</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>Blood Alkaline Phosphatase Increased</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>23</p></td></tr><tr><td style="vertical-align:top"><p>Blood Potassium Decreased</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>23</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate Aminotransferase Increased</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>17</p></td></tr><tr><td style="vertical-align:top"><p>Blood Bilirubin Increased</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Blood Magnesium Decreased</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Blood Glucose Increased</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Bilirubin Conjugated Increased</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Blood Urea Increased</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Blood Creatinine Increased</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site</strong></p><p><strong>Conditions</strong></p></td><td style="vertical-align:top"><p><strong>57</strong></p></td><td style="vertical-align:top"><p><strong>63</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>29</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>31</p></td></tr><tr><td style="vertical-align:top"><p>Edema Peripheral</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Mucosal Inflammation</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top"><p><strong>50</strong></p></td><td style="vertical-align:top"><p><strong>55</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal Pain</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>17</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, Thoracic and Mediastinal</strong></p><p><strong>Disorders</strong></p></td><td style="vertical-align:top"><p><strong>47</strong></p></td><td style="vertical-align:top"><p><strong>49</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top"><p><strong>42</strong></p></td><td style="vertical-align:top"><p><strong>37</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top"><p><strong>25</strong></p></td><td style="vertical-align:top"><p><strong>27</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td style="vertical-align:top"><p><strong>21</strong></p></td><td style="vertical-align:top"><p><strong>24</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypokalemia</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>23</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top"><p><strong>16</strong></p></td><td style="vertical-align:top"><p><strong>19</strong></p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>9</p></td></tr></tbody></table><p>Within any system organ class, individuals may experience more than 1 adverse reaction.</p><p>* 70 mg on Day 1, then 50 mg once daily for the remainder of treatment; daily dose was increased to 70 mg for 73 patients.</p><p><strong><sup>&dagger;</sup> </strong>3 mg/kg/day; daily dose was increased to 5 mg/kg for 74 patients.</p><p>The proportion of patients who experienced an infusion-related adverse reaction (defined as a systemic event, such as pyrexia, chills, flushing, hypotension, hypertension, tachycardia, dyspnea, tachypnea, rash, or anaphylaxis, that developed during the study therapy infusion and one hour following infusion) was significantly lower in the group treated with Caspofungin acetate for Injection (35%) than in the group treated with AmBisome (52%).</p><p>To evaluate the effect of Caspofungin acetate for Injection and AmBisome on renal function, nephrotoxicity was defined as doubling of serum creatinine relative to baseline or an increase of greater than or equal to 1 mg/dL in serum creatinine if baseline serum creatinine was above the upper limit of the normal range. Among patients whose baseline creatinine clearance was greater than 30 mL/min, the incidence of nephrotoxicity was significantly lower in the group treated with Caspofungin acetate for Injection (3%) than in the group treated with AmBisome (12%).</p><p><em><u>Candidemia and Other Candida Infections</u></em></p><p>In the randomized, double-blinded invasive candidiasis study, patients received either Caspofungin acetate for Injection 50 mg/day (following a 70-mg loading dose) or amphotericin B 0.6 to 1 mg/kg/day. Adverse reactions occurring in 10% or greater of the patients in either treatment group are presented in Table 2.</p><p>Table 2: Adverse Reactions Among Patients with Candidemia or Other Candida Infections Incidence 10% or Greater for at Least One Treatment Group</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>Caspofungin acetate for Injection 50 mg<sup>&dagger;</sup></strong></p><p><strong>N=114 (percent)</strong></p></td><td style="vertical-align:top"><p><strong>Amphotericin B N=125</strong></p><p><strong>(percent)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Systems, Any Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>96</strong></p></td><td style="vertical-align:top"><p><strong>99</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><strong>67</strong></p></td><td style="vertical-align:top"><p><strong>82</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood Potassium Decreased</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td style="vertical-align:top"><p>Blood Alkaline Phosphatase Increased</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin Decreased</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>23</p></td></tr><tr><td style="vertical-align:top"><p>Alanine Aminotransferase Increased</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate Aminotransferase Increased</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Blood Bilirubin Increased</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>17</p></td></tr><tr><td style="vertical-align:top"><p>Hematocrit Decreased</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>18</p></td></tr><tr><td style="vertical-align:top"><p>Blood Creatinine Increased</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>28</p></td></tr><tr><td style="vertical-align:top"><p>Red Blood Cells Urine Positive</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Blood Urea Increased</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>23</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:629px"><tbody><tr><td style="vertical-align:top; width:236px"><p>Bilirubin Conjugated Increased</p></td><td style="vertical-align:top; width:250px"><p>8</p></td><td style="vertical-align:top; width:141px"><p>14</p></td></tr><tr><td style="vertical-align:top; width:236px"><p><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top; width:250px"><p><strong>49</strong></p></td><td style="vertical-align:top; width:141px"><p><strong>53</strong></p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Vomiting</p></td><td style="vertical-align:top; width:250px"><p>17</p></td><td style="vertical-align:top; width:141px"><p>16</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Diarrhea</p></td><td style="vertical-align:top; width:250px"><p>14</p></td><td style="vertical-align:top; width:141px"><p>10</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Nausea</p></td><td style="vertical-align:top; width:250px"><p>9</p></td><td style="vertical-align:top; width:141px"><p>17</p></td></tr><tr><td style="vertical-align:top; width:236px"><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td style="vertical-align:top; width:250px"><p><strong>47</strong></p></td><td style="vertical-align:top; width:141px"><p><strong>63</strong></p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Pyrexia</p></td><td style="vertical-align:top; width:250px"><p>13</p></td><td style="vertical-align:top; width:141px"><p>33</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Edema Peripheral</p></td><td style="vertical-align:top; width:250px"><p>11</p></td><td style="vertical-align:top; width:141px"><p>12</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Chills</p></td><td style="vertical-align:top; width:250px"><p>9</p></td><td style="vertical-align:top; width:141px"><p>30</p></td></tr><tr><td style="vertical-align:top; width:236px"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td style="vertical-align:top; width:250px"><p><strong>40</strong></p></td><td style="vertical-align:top; width:141px"><p><strong>54</strong></p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Tachypnea</p></td><td style="vertical-align:top; width:250px"><p>1</p></td><td style="vertical-align:top; width:141px"><p>11</p></td></tr><tr><td style="vertical-align:top; width:236px"><p><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top; width:250px"><p>26</p></td><td style="vertical-align:top; width:141px"><p>34</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Tachycardia</p></td><td style="vertical-align:top; width:250px"><p>8</p></td><td style="vertical-align:top; width:141px"><p>12</p></td></tr><tr><td style="vertical-align:top; width:236px"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top; width:250px"><p><strong>25</strong></p></td><td style="vertical-align:top; width:141px"><p><strong>28</strong></p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Rash</p></td><td style="vertical-align:top; width:250px"><p>4</p></td><td style="vertical-align:top; width:141px"><p>10</p></td></tr><tr><td style="vertical-align:top; width:236px"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top; width:250px"><p>25</p></td><td style="vertical-align:top; width:141px"><p>38</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Hypotension</p></td><td style="vertical-align:top; width:250px"><p>10</p></td><td style="vertical-align:top; width:141px"><p>16</p></td></tr><tr><td style="vertical-align:top; width:236px"><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td style="vertical-align:top; width:250px"><p>15</p></td><td style="vertical-align:top; width:141px"><p>13</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Anemia</p></td><td style="vertical-align:top; width:250px"><p>11</p></td><td style="vertical-align:top; width:141px"><p>9</p></td></tr></tbody></table><p>Within any system organ class, individuals may experience more than 1 adverse reaction.</p><p>* Intra-abdominal abscesses, peritonitis and pleural space infections.</p><p>&dagger; Patients received Caspofungin acetate for Injection 70 mg on Day 1, then 50 mg once daily for the remainder of their treatment.</p><p>The proportion of patients who experienced an infusion-related adverse reaction (defined as a systemic event, such as pyrexia, chills, flushing, hypotension, hypertension, tachycardia, dyspnea, tachypnea, rash, or anaphylaxis, that developed during the study therapy infusion and one hour following infusion) was significantly lower in the group treated with Caspofungin acetate for Injection (20%) than in the group treated with amphotericin B (49%).</p><p>To evaluate the effect of Caspofungin acetate for Injection and amphotericin B on renal function, nephrotoxicity was defined as doubling of serum creatinine relative to baseline or an increase of greater than or equal to 1 mg/dL in serum creatinine if baseline serum creatinine was above the upper limit of the normal range. In a subgroup of patients whose baseline creatinine clearance was greater than 30 mL/min, the incidence of nephrotoxicity was significantly lower in the group treated with Caspofungin acetate for Injection than in the group treated with amphotericin B.</p><p>&nbsp;</p><p>In a second randomized, double-blinded invasive candidiasis study, patients received either Caspofungin acetate for Injection 50 mg/day (following a 70-mg loading dose) or Caspofungin acetate for Injection 150 mg/day. The proportion of patients who experienced any adverse reaction was similar in the 2 treatment groups; however, this study was not large enough to detect differences in rare or unexpected adverse reactions. Adverse reactions occurring in 5 % or greater of the patients in either treatment group are presented in Table 3.</p><p>Table 3: Adverse Reactions Among Patients with Candidemia or other Candida Infections Incidence 5% or Greater for at Least One Treatment Group</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>Caspofungin acetate for Injection 50 mg<sup>&dagger;</sup> N=104 (percent)</strong></p></td><td style="vertical-align:top"><p><strong>Caspofungin acetate for Injection 150 mg N=100 (percent)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Systems, Any Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>83</strong></p></td><td style="vertical-align:top"><p><strong>83</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td style="vertical-align:top"><p><strong>33</strong></p></td><td style="vertical-align:top"><p><strong>27</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top"><p><strong>30</strong></p></td><td style="vertical-align:top"><p><strong>33</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p><strong>11</strong></p></td><td style="vertical-align:top"><p><strong>6</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p><strong>6</strong></p></td><td style="vertical-align:top"><p><strong>7</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p><strong>5</strong></p></td><td style="vertical-align:top"><p><strong>7</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><strong>28</strong></p></td><td style="vertical-align:top"><p><strong>35</strong></p></td></tr><tr><td style="vertical-align:top"><p>Alkaline Phosphatase Increased</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p><strong>9</strong></p></td></tr><tr><td style="vertical-align:top"><p>Aspartate Aminotransferase Increased</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p><strong>9</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood potassium decreased</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p><strong>8</strong></p></td></tr><tr><td style="vertical-align:top"><p>Alanine Aminotransferase Increased</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p><strong>7</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorder</strong></p></td><td style="vertical-align:top"><p><strong>19</strong></p></td><td style="vertical-align:top"><p><strong>18</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6</p></td></tr></tbody></table><p>Within any system organ class, individuals may experience more than 1 adverse event</p><p>* Intra-abdominal abscesses, peritonitis and pleural space infections.</p><p>&dagger; Patients received Caspofungin acetate for Injection 70 mg on Day 1, then 50 mg once daily for the remainder of their treatment.</p><p><em>Esophageal Candidiasis and Oropharyngeal Candidiasis</em></p><p>Adverse reactions occurring in 10% or greater of patients with esophageal and/or oropharyngeal candidiasis are presented in Table 4.</p><p>Table 4: Adverse Reactions Among Patients with Esophageal and/or Oropharyngeal Candidiasis Incidence 10% or Greater for at Least One Treatment Group</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>Caspofungin acetate for Injection</strong></p><p><strong>50 mg* N=83 (percent)</strong></p></td><td style="vertical-align:top"><p><strong>Fluconazole IV 200 mg</strong><strong>*</strong></p><p><strong>N=94 (percent)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Systems, Any Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>90</strong></p></td><td style="vertical-align:top"><p><strong>93</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:210px"><p><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top; width:205px"><p><strong>58</strong></p></td><td style="vertical-align:top; width:151px"><p><strong>50</strong></p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Diarrhea</p></td><td style="vertical-align:top; width:205px"><p>27</p></td><td style="vertical-align:top; width:151px"><p>18</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Nausea</p></td><td style="vertical-align:top; width:205px"><p>15</p></td><td style="vertical-align:top; width:151px"><p>15</p></td></tr><tr><td style="vertical-align:top; width:210px"><p><strong>Investigations</strong></p></td><td style="vertical-align:top; width:205px"><p><strong>53</strong></p></td><td style="vertical-align:top; width:151px"><p><strong>61</strong></p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Hemoglobin Decreased</p></td><td style="vertical-align:top; width:205px"><p>21</p></td><td style="vertical-align:top; width:151px"><p>16</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Hematocrit Decreased</p></td><td style="vertical-align:top; width:205px"><p>18</p></td><td style="vertical-align:top; width:151px"><p>16</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Aspartate Aminotransferase Increased</p></td><td style="vertical-align:top; width:205px"><p>13</p></td><td style="vertical-align:top; width:151px"><p>19</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Blood Alkaline Phosphatase Increased</p></td><td style="vertical-align:top; width:205px"><p>13</p></td><td style="vertical-align:top; width:151px"><p>17</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Alanine Aminotransferase Increased</p></td><td style="vertical-align:top; width:205px"><p>12</p></td><td style="vertical-align:top; width:151px"><p>17</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>White Blood Cell Count Decreased</p></td><td style="vertical-align:top; width:205px"><p>12</p></td><td style="vertical-align:top; width:151px"><p>19</p></td></tr><tr><td style="vertical-align:top; width:210px"><p><strong>General Dis orders and Administration</strong></p><p><strong>Site Conditions</strong></p></td><td style="vertical-align:top; width:205px"><p><strong>31</strong></p></td><td style="vertical-align:top; width:151px"><p><strong>36</strong></p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Pyrexia</p></td><td style="vertical-align:top; width:205px"><p>21</p></td><td style="vertical-align:top; width:151px"><p>21</p></td></tr><tr><td style="vertical-align:top; width:210px"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top; width:205px"><p><strong>19</strong></p></td><td style="vertical-align:top; width:151px"><p><strong>15</strong></p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Phlebitis</p></td><td style="vertical-align:top; width:205px"><p>18</p></td><td style="vertical-align:top; width:151px"><p>11</p></td></tr><tr><td style="vertical-align:top; width:210px"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top; width:205px"><p><strong>18</strong></p></td><td style="vertical-align:top; width:151px"><p><strong>17</strong></p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Headache</p></td><td style="vertical-align:top; width:205px"><p>15</p></td><td style="vertical-align:top; width:151px"><p>9</p></td></tr></tbody></table><p>Within any system organ class, individuals may experience more than 1 adverse reaction.</p><p><strong>* </strong>Derived from a comparator-controlled clinical study.</p><p>&nbsp;</p><p><em>Invasive Aspergillosis</em></p><p>In an open-label, noncomparative aspergillosis study, in which 69 patients received Caspofungin acetate for Injection (70-mg loading dose on Day 1 followed by 50 mg daily), the following adverse reactions were observed with an incidence of 12.5% or greater: blood alkaline phosphatase increased (22%), hypotension (20%), respiratory failure (20%), pyrexia (17%), diarrhea (15%), nausea (15%), headache (15%), rash (13%), alanine aminotransferase increased (13%), aspartate aminotransferase increased (13%), blood bilirubin increased (13%), and blood potassium decreased (13%). Also reported in this patient population were pulmonary edema, ARDS (adult respiratory distress syndrome), and radiographic infiltrates.</p><p><u>Pediatric Patients (3 months to 17 years of age)</u></p><p>The overall safety of Caspofungin acetate for Injection was assessed in 171 pediatric patients who received single or multiple doses of Caspofungin acetate for Injection. The distribution among the 153 pediatric patients who were over the age of 3 months was as follows: 104 febrile, neutropenic patients; 38 patients with candidemia and/or intra-abdominal abscesses, peritonitis, or pleural space infections; 1 patient with esophageal candidiasis; and 10 patients with invasive aspergillosis. The overall safety profile of Caspofungin acetate for Injection in</p><p>&nbsp;</p><p>pediatric patients is comparable to that in adult patients. Table 5 shows the incidence of adverse reactions reported in 7.5% or greater of pediatric patients in clinical studies.</p><p>One patient (0.6%) receiving Caspofungin acetate for Injection, and three patients (12%) receiving AmBisome developed a serious drug-related adverse reaction. Two patients (1%) were discontinued from Caspofungin acetate for Injection and three patients (12%) were discontinued from AmBisome due to a drug-related adverse reaction. The proportion of patients who experienced an infusion-related adverse reaction (defined as a systemic event, such as pyrexia, chills, flushing, hypotension, hypertension, tachycardia, dyspnea, tachypnea, rash, or anaphylaxis, that developed during the study therapy infusion and one hour following infusion) was 22% in the group treated with Caspofungin acetate for Injection and 35% in the group treated with AmBisome.</p><p>Table 5: Adverse Reactions Among Pediatric Patients (0 months to 17 years of age) Incidence 7.5% or Greater for at Least One Treatment Group</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>Noncomparative </strong><strong>Clinical Studies</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Comparator-Controlled Clinical Study of Empirical Therapy</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Caspofungin acetate for Injection</strong></p><p><strong>Any Dose N=115 (percent)</strong></p></td><td style="vertical-align:top"><p><strong>Caspofungin acetate for Injection</strong></p><p><strong>50 mg/m<sup>2</sup>* N=56 (percent)</strong></p></td><td style="vertical-align:top"><p><strong>AmBisome </strong><strong>3 mg/kg N=26</strong></p><p><strong>(percent)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Systems, Any Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>95</strong></p></td><td style="vertical-align:top"><p><strong>96</strong></p></td><td style="vertical-align:top"><p><strong>89</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><strong>55</strong></p></td><td style="vertical-align:top"><p><strong>41</strong></p></td><td style="vertical-align:top"><p><strong>50</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood Potassium Decreased</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>27</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate Aminotransferase Increased</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Alanine Aminotransferase Increased</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Blood Potassium Increased</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td style="vertical-align:top"><p><strong>47</strong></p></td><td style="vertical-align:top"><p><strong>59</strong></p></td><td style="vertical-align:top"><p><strong>42</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>23</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Mucosal Inflammation</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Edema</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top"><p><strong>42</strong></p></td><td style="vertical-align:top"><p><strong>59</strong></p></td><td style="vertical-align:top"><p><strong>42</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal Pain</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and Infestations</strong></p></td><td style="vertical-align:top"><p><strong>40</strong></p></td><td style="vertical-align:top"><p><strong>30</strong></p></td><td style="vertical-align:top"><p><strong>35</strong></p></td></tr><tr><td style="vertical-align:top"><p>Central Line Infection</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top"><p><strong>33</strong></p></td><td style="vertical-align:top"><p><strong>41</strong></p></td><td style="vertical-align:top"><p><strong>39</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>8</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:649px"><tbody><tr><td style="vertical-align:top; width:219px"><p>Erythema</p></td><td style="vertical-align:top; width:160px"><p>4</p></td><td style="vertical-align:top; width:149px"><p>9</p></td><td style="vertical-align:top; width:120px"><p>0</p></td></tr><tr><td style="vertical-align:top; width:219px"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top; width:160px"><p><strong>24</strong></p></td><td style="vertical-align:top; width:149px"><p><strong>21</strong></p></td><td style="vertical-align:top; width:120px"><p><strong>19</strong></p></td></tr><tr><td style="vertical-align:top; width:219px"><p>Hypotension</p></td><td style="vertical-align:top; width:160px"><p>12</p></td><td style="vertical-align:top; width:149px"><p>9</p></td><td style="vertical-align:top; width:120px"><p>8</p></td></tr><tr><td style="vertical-align:top; width:219px"><p>Hypertension</p></td><td style="vertical-align:top; width:160px"><p>10</p></td><td style="vertical-align:top; width:149px"><p>9</p></td><td style="vertical-align:top; width:120px"><p>4</p></td></tr><tr><td style="vertical-align:top; width:219px"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td style="vertical-align:top; width:160px"><p>22</p></td><td style="vertical-align:top; width:149px"><p>11</p></td><td style="vertical-align:top; width:120px"><p>23</p></td></tr><tr><td style="vertical-align:top; width:219px"><p>Hypokalemia</p></td><td style="vertical-align:top; width:160px"><p>8</p></td><td style="vertical-align:top; width:149px"><p>5</p></td><td style="vertical-align:top; width:120px"><p>4</p></td></tr><tr><td style="vertical-align:top; width:219px"><p><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top; width:160px"><p><strong>17</strong></p></td><td style="vertical-align:top; width:149px"><p><strong>13</strong></p></td><td style="vertical-align:top; width:120px"><p><strong>19</strong></p></td></tr><tr><td style="vertical-align:top; width:219px"><p>Tachycardia</p></td><td style="vertical-align:top; width:160px"><p>4</p></td><td style="vertical-align:top; width:149px"><p>11</p></td><td style="vertical-align:top; width:120px"><p>19</p></td></tr><tr><td style="vertical-align:top; width:219px"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top; width:160px"><p><strong>13</strong></p></td><td style="vertical-align:top; width:149px"><p><strong>16</strong></p></td><td style="vertical-align:top; width:120px"><p><strong>8</strong></p></td></tr><tr><td style="vertical-align:top; width:219px"><p>Headache</p></td><td style="vertical-align:top; width:160px"><p>5</p></td><td style="vertical-align:top; width:149px"><p>9</p></td><td style="vertical-align:top; width:120px"><p>4</p></td></tr><tr><td style="vertical-align:top; width:219px"><p><strong>Musculoskeletal and Connective Tissue Dis orders</strong></p></td><td style="vertical-align:top; width:160px"><p>11</p></td><td style="vertical-align:top; width:149px"><p>14</p></td><td style="vertical-align:top; width:120px"><p>12</p></td></tr><tr><td style="vertical-align:top; width:219px"><p>Back Pain</p></td><td style="vertical-align:top; width:160px"><p>4</p></td><td style="vertical-align:top; width:149px"><p>0</p></td><td style="vertical-align:top; width:120px"><p>8</p></td></tr><tr><td style="vertical-align:top; width:219px"><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td style="vertical-align:top; width:160px"><p><strong>10</strong></p></td><td style="vertical-align:top; width:149px"><p><strong>2</strong></p></td><td style="vertical-align:top; width:120px"><p><strong>15</strong></p></td></tr><tr><td style="vertical-align:top; width:219px"><p>Anemia</p></td><td style="vertical-align:top; width:160px"><p>2</p></td><td style="vertical-align:top; width:149px"><p>0</p></td><td style="vertical-align:top; width:120px"><p>8</p></td></tr></tbody></table><p>Within any system organ class, individuals may experience more than 1 adverse reaction.</p><p>*70 mg/m on Day 1, then 50 mg/m<sup>2</sup> once daily for the remainder of the treatment.</p><p>&nbsp;</p><p>Overall Safety Experience of Caspofungin acetate for Injection in Clinical Trials</p><p>The overall safety of Caspofungin acetate for Injection was assessed in 2036 individuals (including 1642 adult or pediatric patients and 394 volunteers) from 34 clinical studies. These individuals received single or multiple (once daily) doses of Caspofungin acetate for Injection, ranging from 5 mg to 210 mg. Full safety data is available from 1951 individuals, as the safety data from 85 patients enrolled in 2 compassionate use studies was limited solely to serious adverse reactions. Adverse reactions which occurred in 5% or greater of all individuals who received Caspofungin acetate for Injection in these trials are shown in Table 6.</p><p>Overall, 1665 of the 1951 (85%) patients/volunteers who received Caspofungin acetate for Injection experienced an adverse reaction.</p><p><strong>Table 6: Adverse Reactions in Patients Who Received Caspofungin acetate for Injection </strong><strong>in Clinical Trials<sup>&dagger;</sup> Incidence 5% or Greater for at Least One Treatment Group</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reactions<sup>&Dagger;</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Caspofungin acetate for Injection (N=1951)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>(n)</strong></p></td><td style="vertical-align:top"><p><strong>(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Systems, Any Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>1665</strong></p></td><td style="vertical-align:top"><p><strong>(85)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><strong>901</strong></p></td><td style="vertical-align:top"><p><strong>(46)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Alanine Aminotransferase Increased</p></td><td style="vertical-align:top"><p>258</p></td><td style="vertical-align:top"><p>(13)</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate Aminotransferase Increased</p></td><td style="vertical-align:top"><p>233</p></td><td style="vertical-align:top"><p>(12)</p></td></tr><tr><td style="vertical-align:top"><p>Blood Alkaline Phosphatase Increased</p></td><td style="vertical-align:top"><p>232</p></td><td style="vertical-align:top"><p>(12)</p></td></tr><tr><td style="vertical-align:top"><p>Blood Potassium Decreased</p></td><td style="vertical-align:top"><p>220</p></td><td style="vertical-align:top"><p>(11)</p></td></tr><tr><td style="vertical-align:top"><p>Blood Bilirubin Increased</p></td><td style="vertical-align:top"><p>117</p></td><td style="vertical-align:top"><p>(6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td style="vertical-align:top"><p><strong>843</strong></p></td><td style="vertical-align:top"><p><strong>(43)</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:574px"><tbody><tr><td style="vertical-align:top; width:315px"><p>Pyrexia</p></td><td style="vertical-align:top; width:131px"><p>381</p></td><td style="vertical-align:top; width:126px"><p>(20)</p></td></tr><tr><td style="vertical-align:top; width:315px"><p>Chills</p></td><td style="vertical-align:top; width:131px"><p>192</p></td><td style="vertical-align:top; width:126px"><p>(10)</p></td></tr><tr><td style="vertical-align:top; width:315px"><p>Edema Peripheral</p></td><td style="vertical-align:top; width:131px"><p>110</p></td><td style="vertical-align:top; width:126px"><p>(6)</p></td></tr><tr><td style="vertical-align:top; width:315px"><p><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top; width:131px"><p><strong>745</strong></p></td><td style="vertical-align:top; width:126px"><p><strong>(39)</strong></p></td></tr><tr><td style="vertical-align:top; width:315px"><p>Diarrhea</p></td><td style="vertical-align:top; width:131px"><p>273</p></td><td style="vertical-align:top; width:126px"><p><strong>(14)</strong></p></td></tr><tr><td style="vertical-align:top; width:315px"><p>Nausea</p></td><td style="vertical-align:top; width:131px"><p>166</p></td><td style="vertical-align:top; width:126px"><p><strong>(9)</strong></p></td></tr><tr><td style="vertical-align:top; width:315px"><p>Vomiting</p></td><td style="vertical-align:top; width:131px"><p>146</p></td><td style="vertical-align:top; width:126px"><p><strong>(8)</strong></p></td></tr><tr><td style="vertical-align:top; width:315px"><p>Abdominal Pain</p></td><td style="vertical-align:top; width:131px"><p>112</p></td><td style="vertical-align:top; width:126px"><p><strong>(6)</strong></p></td></tr><tr><td style="vertical-align:top; width:315px"><p><strong>Infections and Infestations</strong></p></td><td style="vertical-align:top; width:131px"><p><strong>730</strong></p></td><td style="vertical-align:top; width:126px"><p><strong>(37)</strong></p></td></tr><tr><td style="vertical-align:top; width:315px"><p>Pneumonia</p></td><td style="vertical-align:top; width:131px"><p>115</p></td><td style="vertical-align:top; width:126px"><p>(6)</p></td></tr><tr><td style="vertical-align:top; width:315px"><p><strong>Respiratory, Thoracic, and Mediastinal Disorders</strong></p></td><td style="vertical-align:top; width:131px"><p><strong>613</strong></p></td><td style="vertical-align:top; width:126px"><p><strong>(31)</strong></p></td></tr><tr><td style="vertical-align:top; width:315px"><p>Cough</p></td><td style="vertical-align:top; width:131px"><p>111</p></td><td style="vertical-align:top; width:126px"><p>(6)</p></td></tr><tr><td style="vertical-align:top; width:315px"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top; width:131px"><p><strong>520</strong></p></td><td style="vertical-align:top; width:126px"><p><strong>(27)</strong></p></td></tr><tr><td style="vertical-align:top; width:315px"><p>Rash</p></td><td style="vertical-align:top; width:131px"><p>159</p></td><td style="vertical-align:top; width:126px"><p>(8)</p></td></tr><tr><td style="vertical-align:top; width:315px"><p>Erythema</p></td><td style="vertical-align:top; width:131px"><p>98</p></td><td style="vertical-align:top; width:126px"><p>(5)</p></td></tr><tr><td style="vertical-align:top; width:315px"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top; width:131px"><p><strong>412</strong></p></td><td style="vertical-align:top; width:126px"><p><strong>(21)</strong></p></td></tr><tr><td style="vertical-align:top; width:315px"><p>Headache</p></td><td style="vertical-align:top; width:131px"><p>193</p></td><td style="vertical-align:top; width:126px"><p>(10)</p></td></tr><tr><td style="vertical-align:top; width:315px"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top; width:131px"><p><strong>344</strong></p></td><td style="vertical-align:top; width:126px"><p><strong>(18)</strong></p></td></tr><tr><td style="vertical-align:top; width:315px"><p>Hypotension</p></td><td style="vertical-align:top; width:131px"><p>118</p></td><td style="vertical-align:top; width:126px"><p>(6)</p></td></tr></tbody></table><p>*Defined as an adverse reaction, regardless of causality, while on Caspofungin acetate for Injection or during the 14 -day post- Caspofungin acetate for Injection follow-up period.</p><p>&dagger; Incidence for each preferred term is 5% or greater among individuals who received at least 1 dose of Caspofungin acetate for Injection.</p><p><strong><sup>&Dagger;</sup> </strong>Within any system organ class, individuals may experience more than 1 adverse event.</p><p>Clinically significant adverse reactions, regardless of causality or incidence which occurred in less than 5% of patients are listed below.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Blood and lymphatic system disorders: </em></strong>anemia, coagulopathy, febrile neutropenia, neutropenia, thrombocytopenia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Cardiac disorders: </em></strong>arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, myocardial infarction, tachycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Gastrointestinal disorders: </em></strong>abdominal distension, abdominal pain upper, constipation, dyspepsia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>General disorders and administration site conditions: </em></strong>asthenia, fatigue, infusion site pain/pruritus/swelling, mucosal inflammation, edema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Hepatobiliary</em></strong><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>hepatic&nbsp;&nbsp;&nbsp;&nbsp; failure, hepatomegaly,&nbsp;&nbsp;&nbsp;&nbsp; hepatotoxicity, hyperbilirubinemia, jaundice</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Infections and infestations: </em></strong>bacteremia, sepsis, urinary tract infection</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Metabolic and nutrition disorders: </em></strong>anorexia, decreased appetite, fluid overload, hypomagnesemia, hypercalcemia, hyperglycemia, hypokalemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Musculoskeletal, connective tissue, and bone disorders: </em></strong>arthralgia, back pain, pain in extremity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Nervous system disorders: </em></strong>convulsion, dizziness, somnolence, tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Psychiatric disorders: </em></strong>anxiety, confusional state, depression, insomnia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Renal and urinary disorders: </em></strong>hematuria, renal failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Respiratory, thoracic, and mediastinal disorders: </em></strong>dyspnea, epistaxis, hypoxia, tachypnea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Skin and subcutaneous tissue disorders: </em></strong>erythema, petechiae, skin lesion, urticaria</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Vascular disorders: </em></strong>flushing, hypertension, phlebitis</p><p>&nbsp;</p><p><strong><u>Postmarketing Experience of Caspofungin acetate for Injection</u></strong></p><p>The following additional adverse reactions have been identified during the post-approval use of Caspofungin acetate for Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Gastrointestinal disorders: </em>pancreatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Hepatobiliary disorders: </em>hepatic necrosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Skin and subcutaneous tissue disorders</em>: erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome, and skin exfoliation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Renal and urinary disorders: </em>clinically significant renal dysfunction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>General disorders and administration site conditions: </em>swelling and peripheral edema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Laboratory abnormalities: </em>gamma-glutamyltransferase increased</p><p><u>To reports any side effect(s):</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the competent authority in Saudi Arabia as per details below:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p><strong>o </strong>Fax: +966-11-205-7662</p><p><strong>o </strong>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp;&nbsp; Toll free phone: 8002490000</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p>To report the Adverse event in other GCC States - Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In 6 healthy subjects who received a single 210-mg dose, no significant adverse reactions were reported. Multiple doses above 150 mg daily have not been studied. Caspofungin is not dialyzable.</p><p>In clinical trials, one pediatric patient (16 years of age) unintentionally received a single dose of caspofungin of 113 mg (on Day 1), followed by 80 mg daily for an additional 7 days. No clinically significant adverse reactions were reported.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antimycotics for systemic use, ATC code: J02AX04</p><p><u>Mechanism of Action</u></p><p>Caspofungin, an echinocandin, inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of susceptible <em>Aspergillus </em>species and <em>Candida </em>species. Beta (1,3)- D-glucan is not present in mammalian cells. Caspofungin has shown activity against <em>Candida </em>species and in regions of active cell growth of the hyphae of <em>Aspergillus fumigatus</em>.</p><p><u>Resistance</u></p><p>There have been reports of clinical failures in patients receiving caspofungin therapy due to the development of drug resistant <em>Candida </em>or <em>Aspergillus </em>species. Some of these reports have identified specific mutations in the Fks subunits, encoded by the fks1 and/or fks2 genes, of the glucan synthase enzyme. These mutations are associated with higher MICs and breakthrough infection. <em>Candida </em>species that exhibit reduced susceptibility to caspofungin as a result of an increase in the chitin content of the fungal cell wall have also been identified, although the significance of this phenomenon <em>in vivo </em>is not well known.</p><p><u>Interaction with Other Antimicrobials</u></p><p>Studies <em>in vitro </em>and <em>in vivo </em>of caspofungin, in combination with amphotericin B, suggest no antagonism of antifungal activity against either <em>A. fumigatus </em>or <em>C. albicans</em>. The clinical significance of these results is unknown.</p><p><u>Antimicrobial Activity</u></p><p>Caspofungin has been shown to be active against most strains of the following microorganisms both <em>in vitro </em>and in clinical infections (see section 4.1)</p><p><em>Aspergillus flavus Aspergillus fumigatus Aspergillus terreus Candida albicans Candida glabrata Candida guilliermondii Candida krusei Candida parapsilosis Candida tropicalis</em></p><p><em>&nbsp;<u>Susceptibility Testing Methods</u></em></p><p>The interpretive standards for caspofungin against <em>Candida </em>species are applicable only to tests performed using Clinical Laboratory and Standards Institute (CLSI) microbroth dilution reference methods. <sup>2,3</sup> for MIC (partial inhibition endpoint) read at 24 hours. No interpretive criteria have been established for <em>Aspergillus </em>species or other filamentous fungi.</p><p>When available, the clinical microbiology laboratory should provide the results of <em>in vitro </em>susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of pathogens. These reports should aid the physician in selecting an antifungal drug product for treatment. The techniques for Broth Microdilution are described below.</p><p><em><u>Broth Microdilution Techniques</u></em></p><p>Quantitative methods are used to determine antifungal minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of <em>Candida </em>spp. to antifungal agents. MICs should be determined using a standardized procedure at 24 hours<sup>2,3</sup>. Standardized</p><p>procedures are based on a microdilution method (broth) with standardized inoculum concentrations and standardized concentrations of caspofungin powder. The MIC values should be interpreted according to the criteria provided in Table 7.</p><p>Table 7: Susceptibility Interpretive Criteria for Caspofungin</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Pathogen</p></td><td colspan="2" style="vertical-align:top"><p>Broth Microdilution MIC* (mcg/mL) at 24 hours</p></td></tr><tr><td style="vertical-align:top"><p>Susceptible (S)</p></td><td style="vertical-align:top"><p>Non-Susceptible (NS)</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida </em>species</p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr></tbody></table><p>* A report of &ldquo;Susceptible&rdquo; indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable</p><p><em><u>Quality Control</u></em></p><p>Quality Control Standardized susceptibility test procedures require the use of quality control organisms to control the technical aspects of the test procedures. Standard caspofungin powder should provide the following range of values noted in Table 8<sup>3</sup>. Quality control microorganisms are specific strains of organisms with intrinsic biological properties relating to resistance mechanisms and their genetic expression within fungi; the specific strains used for microbiological control are not clinically significant.</p><p>Table 8: Acceptable Quality Control Ranges for Caspofungin to be used in Validation of Susceptibility Test Results</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>QC Strain</strong></p></td><td style="vertical-align:top"><p><strong>Broth Microdilution (MIC in mcg/mL) at 24 hours*</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Candida parapsilosis </em>ATCC 22019</p></td><td style="vertical-align:top"><p>0.25 to 1.0</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida krusei </em>ATCC 6258</p></td><td style="vertical-align:top"><p>0.12 to 1.0</p></td></tr></tbody></table><p>* The MIC for caspofungin is the lowest concentration at which a score of 2 (prominent decrease in turbidity [greater than 50% inhibition of growth as compared to the growth control]; see CLSI document M27-A3<sup>2</sup>, Section 7.6.3) is observed after 24 hours of incubation.</p><p><strong><u>Clinical efficacy and safety</u></strong></p><p><u>Empirical Therapy in Febrile, Neutropenic Patients</u></p><p>A double-blind study enrolled 1111 febrile, neutropenic (&lt;500 cells/mm<sup>3</sup>) patients who were randomized to treatment with daily doses of Caspofungin acetate for Injection (50 mg/day following a 70-mg loading dose on Day 1) or AmBisome (3 mg/kg/day). Patients were stratified based on risk category (high-risk patients had undergone allogeneic stem cell</p><p>transplantation or had relapsed acute leukemia) and on receipt of prior antifungal prophylaxis. Twenty-four percent of patients were high risk and 56% had received prior antifungal prophylaxis. Patients who remained febrile or clinically deteriorated following 5 days of therapy could receive 70 mg/day of Caspofungin acetate for Injection or 5 mg/kg/day of AmBisome. Treatment was continued to resolution of neutropenia (but not beyond 28 days unless a fungal infection was documented).</p><p>An overall favorable response required meeting each of the following criteria: no documented breakthrough fungal infections up to 7 days after completion of treatment, survival for 7 days after completion of study therapy, no discontinuation of the study drug because of drug-related toxicity or lack of efficacy, resolution of fever during the period of neutropenia, and successful treatment of any documented baseline fungal infection.</p><p>Based on the composite response rates, Caspofungin acetate for Injection was as effective as AmBisome in empirical therapy of persistent febrile neutropenia (see Table 9).</p><p>Table 9: Favorable Response of Patients with Persistent Fever and Neutropenia</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Caspofungin acetate</strong></p><p><strong>for Injection*</strong></p></td><td style="vertical-align:top"><p><strong>AmBisome*</strong></p></td><td style="vertical-align:top"><p><strong>% Difference</strong></p><p><strong>(Confidence Interval)<sup>&dagger;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of Patients &Dagger;</p></td><td style="vertical-align:top"><p>556</p></td><td style="vertical-align:top"><p>539</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Overall Favorable Response</p></td><td style="vertical-align:top"><p>190 (33.9%)</p></td><td style="vertical-align:top"><p>181 (33.7%)</p></td><td style="vertical-align:top"><p>0.2 (-5.6, 6.0)</p></td></tr><tr><td style="vertical-align:top"><p>No documented breakthrough fungal</p><p>infection</p></td><td style="vertical-align:top"><p>527 (94.8%)</p></td><td style="vertical-align:top"><p>515 (95.5%)</p></td><td style="vertical-align:top"><p>-0.8</p></td></tr><tr><td style="vertical-align:top"><p>Survival 7 days after end of</p><p>treatment</p></td><td style="vertical-align:top"><p>515 (92.6%)</p></td><td style="vertical-align:top"><p>481 (89.2%)</p></td><td style="vertical-align:top"><p>3.4</p></td></tr><tr><td style="vertical-align:top"><p>No discontinuation due to</p><p>toxicity or lack of efficacy</p></td><td style="vertical-align:top"><p>499 (89.7%)</p></td><td style="vertical-align:top"><p>461 (85.5%)</p></td><td style="vertical-align:top"><p>4.2</p></td></tr><tr><td style="vertical-align:top"><p>Resolution of fever during</p><p>neutropenia</p></td><td style="vertical-align:top"><p>229 (41.2%)</p></td><td style="vertical-align:top"><p>223 (41.4%)</p></td><td style="vertical-align:top"><p>-0.2</p></td></tr></tbody></table><p>*Caspofungin acetate for Injection: 70 mg on Day 1, then 50 mg once daily for the remainder of treatment (daily dose increased to 70 mg for 73 patients); AmBisome: 3 mg/kg/day (daily dose increased to 5 mg/kg for 74 patients).</p><p><sup>&dagger;</sup>Overall Response: estimated % difference adjusted for strata and expressed as Caspofungin acetate for Injection</p><p>&ndash; AmBisome (95.2% CI); Individual criteria presented above are not mutually exclusive. The percent difference calculated as Caspofungin acetate for Injection &ndash; AmBisome.</p><p><sup>&Dagger;</sup>Analysis population excluded subjects who did not have fever or neutropenia at study entry.</p><p>The rate of successful treatment of documented baseline infections, a component of the primary endpoint, was not statistically different between treatment groups.</p><p>&nbsp;</p><p>The response rates did not differ between treatment groups based on either of the stratification variables: risk category or prior antifungal prophylaxis.</p><p><u>Candidemia and the Following other <em>Candida </em>Infections: Intra-Abdominal Abscesses,</u> <u>Peritonitis and Pleural Space Infections</u></p><p>In a randomized, double-blind study, patients with a proven diagnosis of invasive candidiasis received daily doses of Caspofungin acetate for Injection (50 mg/day following a 70-mg loading dose on Day 1) or amphotericin B deoxycholate (0.6 to 0.7 mg/kg/day for non- neutropenic patients and 0.7 to 1 mg/kg/day for neutropenic patients). Patients were stratified by both neutropenic status and APACHE II score. Patients with Candida endocarditis, meningitis, or osteomyelitis were excluded from this study.</p><p>Patients who met the entry criteria and received one or more doses of IV study therapy were included in the modified intention-to-treat [MITT] analysis of response at the end of IV study therapy. A favorable response at this time point required both symptom/sign resolution/improvement and microbiological clearance of the <em>Candida </em>infection.</p><p>Two hundred thirty-nine patients were enrolled. Patient disposition is shown in Table 10.</p><p>&nbsp;</p><p>Table 10: Disposition in Candidemia and Other <em>Candida </em>Infections (Intra-abdominal abscesses, peritonitis, and pleural space infections)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Caspofungin acetate for</strong></p><p><strong>Injection*</strong></p></td><td style="vertical-align:top"><p><strong>Amphotericin B</strong></p></td></tr><tr><td style="vertical-align:top"><p>Randomized patients</p></td><td style="vertical-align:top"><p>114</p></td><td style="vertical-align:top"><p>125</p></td></tr><tr><td style="vertical-align:top"><p>Patients completing study&dagger;</p></td><td style="vertical-align:top"><p>63 (55.3%)</p></td><td style="vertical-align:top"><p>69 (55.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>DISCONTINUATIONS OF STUDY&dagger;</strong></p></td></tr><tr><td style="vertical-align:top"><p>All Study Discontinuations</p></td><td style="vertical-align:top"><p>51 (44.7%)</p></td><td style="vertical-align:top"><p>56 (44.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Study Discontinuations due to clinical</p><p>adverse events</p></td><td style="vertical-align:top"><p>39 (34.2%)</p></td><td style="vertical-align:top"><p>43 (34.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Study Discontinuations due to laboratory</p><p>adverse events</p></td><td style="vertical-align:top"><p>0 (0%)</p></td><td style="vertical-align:top"><p>1 (0.8%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>DISCONTINUATIONS OF STUDY THERAPY</strong></p></td></tr><tr><td style="vertical-align:top"><p>All Study Therapy Discontinuations</p></td><td style="vertical-align:top"><p>48 (42.1%)</p></td><td style="vertical-align:top"><p>58 (46.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Study Therapy Discontinuations due to</p><p>clinical adverse events</p></td><td style="vertical-align:top"><p>30 (26.3%)</p></td><td style="vertical-align:top"><p>37 (29.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Study Therapy Discontinuations due to</p><p>laboratory adverse events</p></td><td style="vertical-align:top"><p>1 (0.9%)</p></td><td style="vertical-align:top"><p>7 (5.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Study Therapy Discontinuations due to all</p><p>drug related<sup>&Dagger;</sup> adverse events</p></td><td style="vertical-align:top"><p>3 (2.6%)</p></td><td style="vertical-align:top"><p>29 (23.2%)</p></td></tr></tbody></table><p>&nbsp;</p><p>*Patients received Caspofungin acetate for Injection 70 mg on Day 1, then 50 mg once daily for the remainder of their treatment.</p><p><sup>&dagger;</sup>Study defined as study treatment period and 6-8 week follow-up period.</p><p><sup>&Dagger;</sup>Determined by the investigator to be possibly, probably, or definitely drug-related.</p><p>&nbsp;</p><p>Of the 239 patients enrolled, 224 met the criteria for inclusion in the MITT population (109 treated with Caspofungin acetate for Injection and 115 treated with amphotericin B). Of these 224 patients, 186 patients had candidemia (92 treated with Caspofungin acetate for Injection and 94 treated with amphotericin B). The majority of the patients with candidemia were non- neutropenic (87%) and had an APACHE II score less than or equal to 20 (77%) in both arms. Most candidemia infections were caused by <em>C. albicans </em>(39%), followed by <em>C. parapsilosis </em>(20%), <em>C. tropicalis </em>(17%), <em>C. glabrata </em>(8%), and <em>C. krusei </em>(3%).</p><p>At the end of IV study therapy, Caspofungin acetate for Injection was comparable to amphotericin B in the treatment of candidemia in the MITT population. For the other efficacy time points (Day 10 of IV study therapy, end of all antifungal therapy, 2-week post-therapy follow-up, and 6- to 8-week post-therapy follow-up), Caspofungin acetate for Injection was as effective as amphotericin B.</p><p>Outcome, relapse and mortality data are shown in Table 11.</p><p>&nbsp;</p><p>Table 11: Outcomes, Relapse, &amp; Mortality in Candidemia and Other Candida Infections (Intra-abdominal abscesses, peritonitis, and pleural space infections)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Caspofungin acetate for Injection*</strong></p></td><td style="vertical-align:top"><p><strong>Amphotericin B</strong></p></td><td style="vertical-align:top"><p><strong>% Difference&dagger; after adjusting for strata</strong></p><p><strong>(Confidence Interval) <sup>&Dagger;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of MITT<sup>&sect;</sup> patients</p></td><td style="vertical-align:top"><p>109</p></td><td style="vertical-align:top"><p>115</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>FAVORABLE OUTCOMES (MITT) AT THE END OF IV STUDY THERAPY</strong></p></td></tr><tr><td style="vertical-align:top"><p>All MITT patients</p></td><td style="vertical-align:top"><p>81/109 (74.3%)</p></td><td style="vertical-align:top"><p>78/115 (67.8%)</p></td><td style="vertical-align:top"><p>7.5 (-5.4, 20.3)</p></td></tr><tr><td style="vertical-align:top"><p>Candidemia</p></td><td style="vertical-align:top"><p>67/92 (72.8%)</p></td><td style="vertical-align:top"><p>63/94 (67.0%)</p></td><td style="vertical-align:top"><p>7.0 (-7.0, 21.1)</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenic</p></td><td style="vertical-align:top"><p>6/14 (43%)</p></td><td style="vertical-align:top"><p>5/10 (50%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Non-neutropenic</p></td><td style="vertical-align:top"><p>61/78 (78%)</p></td><td style="vertical-align:top"><p>58/84 (69%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endophthalmitis</p></td><td style="vertical-align:top"><p>0/1</p></td><td style="vertical-align:top"><p>2/3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Multiple Sites</p></td><td style="vertical-align:top"><p>4/5</p></td><td style="vertical-align:top"><p>4/4</p></td><td rowspan="7" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood / Pleural</p></td><td style="vertical-align:top"><p>1/1</p></td><td style="vertical-align:top"><p>1/1</p></td></tr><tr><td style="vertical-align:top"><p>Blood / Peritoneal</p></td><td style="vertical-align:top"><p>1/1</p></td><td style="vertical-align:top"><p>1/1</p></td></tr><tr><td style="vertical-align:top"><p>Blood / Urine</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>1/1</p></td></tr><tr><td style="vertical-align:top"><p>Peritoneal / Pleural</p></td><td style="vertical-align:top"><p>1/2</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal / Peritoneal</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>1/1</p></td></tr><tr><td style="vertical-align:top"><p>Subphrenic / Peritoneal</p></td><td style="vertical-align:top"><p>1/1</p></td><td style="vertical-align:top"><p>-</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:648px"><tbody><tr><td colspan="4" style="vertical-align:top; width:647px"><p><strong>DISSEMINATED INFECTIONS, RELAPSES AND MORTALITY</strong></p></td></tr><tr><td style="vertical-align:top; width:155px"><p>Disseminated Infections in</p><p>neutropenic patients</p></td><td style="vertical-align:top; width:185px"><p>4/14 (28.6%)</p></td><td style="vertical-align:top; width:101px"><p>3/10 (30.0%)</p></td><td style="vertical-align:top; width:205px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:155px"><p>All relapses <sup>&para;</sup></p></td><td style="vertical-align:top; width:185px"><p>7/81 (8.6%)</p></td><td style="vertical-align:top; width:101px"><p>8/78 (10.3%)</p></td><td rowspan="2" style="vertical-align:top; width:205px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:155px"><p>Culture-confirmed relapse</p></td><td style="vertical-align:top; width:185px"><p>5/81 (6%)</p></td><td style="vertical-align:top; width:101px"><p>2/78 (3%)</p></td></tr><tr><td style="vertical-align:top; width:155px"><p>Overall study<sup>#</sup> mortality in MITT</p><p>Mortality during study therapy</p><p>Mortality attributed to</p><p><em>Candida</em></p></td><td style="vertical-align:top; width:185px"><p>36/109 (33.0%)</p><p>18/109 (17%)</p><p>4/109 (4%)</p></td><td style="vertical-align:top; width:101px"><p>35/115 (30.4%)</p><p>13/115 (11%)</p><p>7/115 (6%)</p></td><td style="vertical-align:top; width:205px"><p>&nbsp;</p></td></tr></tbody></table><p>*Patients received Caspofungin acetate for Injection 70 mg on Day 1, then 50 mg once daily for the remainder of their treatment.</p><p><strong><sup>&dagger;</sup></strong>Calculated as Caspofungin acetate for Injection &ndash; amphotericin B</p><p><strong><sup>&Dagger;</sup></strong>95% CI for candidemia, 95.6% for all patients</p><p><sup>&sect;</sup>Modified intention-to-treat</p><p><sup>&para;</sup>Includes all patients who either developed a culture-confirmed recurrence of <em>Candida </em>infection or</p><p>required antifungal therapy for the treatment of a proven or suspected <em>Candida </em>infection in the follow-up period.</p><p><sup>#</sup>Study defined as study treatment period and 6-8 week follow-up period.</p><p>&nbsp;</p><p>In this study, the efficacy of Caspofungin acetate for Injection in patients with intra-abdominal abscesses, peritonitis and pleural space <em>Candida </em>infections was evaluated in 19 non- neutropenic patients. Two of these patients had concurrent candidemia. <em>Candida </em>was part of a polymicrobial infection that required adjunctive surgical drainage in 11 of these 19 patients. A favorable response was seen in 9 of 9 patients with peritonitis, 3 of 4 with abscesses (liver, parasplenic, and urinary bladder abscesses), 2 of 2 with pleural space infections, 1 of 2 with mixed peritoneal and pleural infection, 1 of 1 with mixed abdominal abscess and peritonitis, and 0 of 1 with <em>Candida </em>pneumonia.</p><p>Overall, across all sites of infection included in the study, the efficacy of Caspofungin acetate for Injection was comparable to that of amphotericin B for the primary endpoint.</p><p>In this study, the efficacy data for Caspofungin acetate for Injection in neutropenic patients with candidemia were limited. In a separate compassionate use study, 4 patients with hepatosplenic candidiasis received prolonged therapy with Caspofungin acetate for Injection following other long-term antifungal therapy; three of these patients had a favorable response.</p><p>In a second randomized, double-blind study, 197 patients with proven invasive candidiasis received Caspofungin acetate for Injection 50 mg/day (following a 70-mg loading dose on Day 1) or Caspofungin acetate for Injection 150 mg/day. The diagnostic criteria, evaluation time</p><p>&nbsp;</p><p>points, and efficacy endpoints were similar to those employed in the prior study. Patients with Candida endocarditis, meningitis, or osteomyelitis were excluded. Although this study was designed to compare the safety of the two doses, it was not large enough to detect differences in rare or unexpected adverse events [see Undesirable effects &ndash; section 4.8]. The efficacy of Caspofungin acetate for Injection at the 150 mg daily dose was not significantly better than the efficacy of the 50-mg daily dose of Caspofungin acetate for Injection. The efficacy of doses higher than 50 mg daily in the other adult patients for whom Caspofungin acetate for Injection is indicated has not been evaluated.</p><p><u>Esophageal Candidiasis (and information on oropharyngeal candidiasis)</u></p><p>The safety and efficacy of Caspofungin acetate for Injection in the treatment of esophageal candidiasis was evaluated in one large, controlled, noninferiority, clinical trial and two smaller dose-response studies.</p><p>In all 3 studies, patients were required to have symptoms and microbiological documentation of esophageal candidiasis; most patients had advanced AIDS (with CD4 counts &lt;50/mm<sup>3</sup>).</p><p>Of the 166 patients in the large study who had culture-confirmed esophageal candidiasis at baseline, 120 had <em>Candida albicans </em>and 2 had <em>Candida tropicalis </em>as the sole baseline pathogen whereas 44 had mixed baseline cultures containing <em>C. albicans </em>and one or more additional <em>Candida species</em>.</p><p>In the large, randomized, double-blind study comparing Caspofungin acetate for Injection 50 mg/day versus intravenous fluconazole 200 mg/day for the treatment of esophageal candidiasis, patients were treated for an average of 9 days (range 7-21 days). Favorable overall response at 5 to 7 days following discontinuation of study therapy required both complete resolution of symptoms and significant endoscopic improvement. The definition of endoscopic response was based on severity of disease at baseline using a 4-grade scale and required at least a two-grade reduction from baseline endoscopic score or reduction to grade 0 for patients with a baseline score of 2 or less. The proportion of patients with a favorable overall response was comparable for Caspofungin acetate for Injection and fluconazole as shown in Table 12.</p><p><strong>Table 12: Favorable Response Rates for Patients with Esophageal Candidiasis*</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Caspofungin acetate for</strong></p><p><strong>Injection</strong></p></td><td style="vertical-align:top"><p><strong>Fluconazole</strong></p></td><td style="vertical-align:top"><p><strong>% Difference<sup>&dagger;</sup></strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Day 5-7 post-treatment</p></td><td style="vertical-align:top"><p>66/81 (81.5%)</p></td><td style="vertical-align:top"><p>80/94 (85.1%)</p></td><td style="vertical-align:top"><p>-3.6 (-14.7, 7.5)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>*</strong>Analysis excluded patients without documented esophageal candidiasis or patients not receiving at least 1 day of study therapy.</p><p><strong><sup>&dagger;</sup></strong>Calculated as Caspofungin acetate for Injection &ndash; fluconazole</p><p>&nbsp;</p><p>The proportion of patients with a favorable symptom response was also comparable (90.1% and 89.4% for Caspofungin acetate for Injection and fluconazole, respectively). In addition, the proportion of patients with a favorable endoscopic response was comparable (85.2% and 86.2% for Caspofungin acetate for Injection and fluconazole, respectively).</p><p>As shown in Table 13, the esophageal candidiasis relapse rates at the Day 14 post-treatment visit were similar for the two groups. At the Day 28 post-treatment visit, the group treated with Caspofungin acetate for Injection had a numerically higher incidence of relapse; however, the difference was not statistically significant.</p><p>Table 13: Relapse Rates at 14- and 28-Days Post-Therapy in Patients with Esophageal Candidiasis at Baseline</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Caspofungin acetate</strong></p><p><strong>for Injection</strong></p></td><td style="vertical-align:top"><p><strong>Fluconazole</strong></p></td><td style="vertical-align:top"><p><strong>% Difference*</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Day 14 post-treatment</p></td><td style="vertical-align:top"><p>7/66 (10.6%)</p></td><td style="vertical-align:top"><p>6/76 (7.9%)</p></td><td style="vertical-align:top"><p>2.7 (-6.9, 12.3)</p></td></tr><tr><td style="vertical-align:top"><p>Day 28 post-treatment</p></td><td style="vertical-align:top"><p>18/64 (28.1%)</p></td><td style="vertical-align:top"><p>12/72 (16.7%)</p></td><td style="vertical-align:top"><p>11.5 (-2.5, 25.4)</p></td></tr></tbody></table><p>*Calculated as Caspofungin acetate for Injection &ndash; fluconazole</p><p>&nbsp;</p><p>In this trial, which was designed to establish noninferiority of Caspofungin acetate for Injection to fluconazole for the treatment of esophageal candidiasis, 122 (70%) patients also had oropharyngeal candidiasis. A favorable response was defined as complete resolution of all symptoms of oropharyngeal disease and all visible oropharyngeal lesions. The proportion of patients with a favorable oropharyngeal response at the 5- to 7-day post-treatment visit was numerically lower for Caspofungin acetate for Injection; however, the difference was not statistically significant. Oropharyngeal candidiasis relapse rates at Day 14 and Day 28 posttreatment visits were statistically significantly higher for Caspofungin acetate for Injection than for fluconazole. The results are shown in Table 14.</p><p>Table 14: Oropharyngeal Candidiasis Response Rates at 5 to 7 Days Post-Therapy and Relapse Rates at 14 and 28 Days Post-Therapy in Patients with Oropharyngeal and</p><p><strong>Esophageal Candidias is at Baseline</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Caspofungin acetate</strong></p><p><strong>for Injection</strong></p></td><td style="vertical-align:top"><p><strong>Fluconazole</strong></p></td><td style="vertical-align:top"><p><strong>% Difference*</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Response Rate Day 5-7 post- treatment</p></td><td style="vertical-align:top"><p>40/56 (71.4%)</p></td><td style="vertical-align:top"><p>55/66 (83.3%)</p></td><td style="vertical-align:top"><p>-11.9 (-26.8, 3.0)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:576px"><tbody><tr><td style="vertical-align:top; width:236px"><p>Relapse Rate Day 14 post- treatment</p><p>Relapse Rate Day 28 post-</p><p>treatment</p></td><td style="vertical-align:top; width:135px"><p>17/40 (42.5%)</p><p><strong>&nbsp;</strong></p><p>23/39 (59.0%)</p></td><td style="vertical-align:top; width:97px"><p>7/53 (13.2%)</p><p><strong>&nbsp;</strong></p><p>18/51 (35.3%)</p></td><td style="vertical-align:top; width:106px"><p>29.3 (11.5, 47.1)</p><p><strong>&nbsp;</strong></p><p>23.7 (3.4, 43.9)</p></td></tr></tbody></table><p>*Calculated as Caspofungin acetate for Injection &ndash; fluconazole</p><p>The results from the two smaller dose-ranging studies corroborate the efficacy of Caspofungin acetate for Injection for esophageal candidiasis that was demonstrated in the larger study.</p><p>Caspofungin acetate for Injection was associated with favorable outcomes in 7 of 10 esophageal <em>C. albicans </em>infections refractory to at least 200 mg of fluconazole given for 7 days, although the <em>in vitro </em>susceptibility of the infecting isolates to fluconazole was not known.</p><p>Invasive Aspergillosis</p><p>Sixty-nine patients between the ages of 18 and 80 with invasive aspergillosis were enrolled in an open label, noncomparative study to evaluate the safety, tolerability, and efficacy of Caspofungin acetate for Injection. Enrolled patients had previously been refractory to or intolerant of other antifungal therapy(ies). Refractory patients were classified as those who had disease progression or failed to improve despite therapy for at least 7 days with amphotericin B, lipid formulations of amphotericin B, itraconazole, or an investigational azole with reported activity against <em>Aspergillus</em>. Intolerance to previous therapy was defined as a doubling of creatinine (or creatinine &ge;2.5 mg/dL while on therapy), other acute reactions, or infusion- related toxicity. To be included in the study, patients with pulmonary disease must have had definite (positive tissue histopathology or positive culture from tissue obtained by an invasive procedure) or probable (positive radiographic or computed tomography evidence with supporting culture from bronchoalveolar lavage or sputum, galactomannan enzyme-linked immunosorbent assay, and/or polymerase chain reaction) invasive aspergillosis. Patients with extrapulmonary disease had to have definite invasive aspergillosis. Patients were administered a single 70-mg loading dose of Caspofungin acetate for Injection and subsequently dosed with 50 mg daily. The mean duration of therapy was 33.7 days, with a range of 1 to 162 days.</p><p>An independent expert panel evaluated patient data, including diagnosis of invasive aspergillosis, response and tolerability to previous antifungal therapy, treatment course on Caspofungin acetate for Injection, and clinical outcome.</p><p>A favorable response was defined as either complete resolution (complete response) or clinically meaningful improvement (partial response) of all signs and symptoms and</p><p>&nbsp;</p><p>attributable radiographic findings. Stable, nonprogressive disease was considered to be an unfavorable response.</p><p>Among the 69 patients enrolled in the study, 63 met entry diagnostic criteria and had outcome data; and of these, 52 patients received treatment for greater than 7 days. Fifty-three (84%) were refractory to previous antifungal therapy and 10 (16%) were intolerant. Forty-five patients had pulmonary disease and 18 had extrapulmonary disease. Underlying conditions were hematologic malignancy (N=24), allogeneic bone marrow transplant or stem cell transplant (N=18), organ transplant (N=8), solid tumor (N=3), or other conditions (N=10). All patients in the study received concomitant therapies for their other underlying conditions. Eighteen patients received tacrolimus and Caspofungin acetate for Injection concomitantly, of whom 8 also received mycophenolate mofetil.</p><p>Overall, the expert panel determined that 41% (26/63) of patients receiving at least one dose of Caspofungin acetate for Injection had a favorable response. For those patients who received greater than 7 days of therapy with Caspofungin acetate for Injection, 50% (26/52) had a favorable response. The favorable response rates for patients who were either refractory to or intolerant of previous therapies were 36% (19/53) and 70% (7/10), respectively. The response rates among patients with pulmonary disease and extrapulmonary disease were 47% (21/45) and 28% (5/18), respectively. Among patients with extrapulmonary disease, 2 of 8 Calculated as Caspofungin acetate for Injection &ndash; fluconazole patients who also had definite, probable, or possible CNS involvement had a favorable response. Two of these 8 patients had progression of disease and manifested CNS involvement while on therapy.</p><p>Caspofungin acetate for Injection is effective for the treatment of invasive aspergillosis in patients who are refractory to or intolerant of itraconazole, amphotericin B, and/or lipid formulations of amphotericin B. However, the efficacy of Caspofungin acetate for Injection for initial treatment of invasive aspergillosis has not been evaluated in comparator-controlled clinical studies.</p><p><u>Pediatric Patients</u></p><p>The safety and efficacy of Caspofungin acetate for Injection were evaluated in pediatric patients 3 months to 17 years of age in two prospective, multicenter clinical trials.</p><p>The first study, which enrolled 82 patients between 2 to 17 years of age, was a randomized, double-blind study comparing Caspofungin acetate for Injection (50 mg/m IV once daily</p><p>&nbsp;</p><p>following a 70-mg/m loading dose on Day 1 [not to exceed 70 mg daily]) to AmBisome (3 mg/kg IV daily) in a 2:1 treatment fashion (56 on caspofungin, 26 on AmBisome) as empirical therapy in pediatric patients with persistent fever and neutropenia. The study design and criteria for efficacy assessment were similar to the study in adult patients. Patients were stratified based on risk category (high-risk patients had undergone allogeneic stem cell transplantation or had relapsed acute leukemia). Twenty-seven percent of patients in both treatment groups were high risk. Favorable overall response rates of pediatric patients with persistent fever and neutropenia are presented in Table 15.</p><p>Table 15: Favorable Overall Response Rates of Pediatric Patients with Persistent Fever&nbsp;and Neutropenia</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:182px"><p>&nbsp;</p></td><td style="vertical-align:top; width:215px"><p><strong>Caspofungin acetate for</strong></p><p><strong>Injection</strong></p></td><td style="vertical-align:top; width:199px"><p><strong>AmBisome*</strong></p></td></tr><tr><td style="vertical-align:top; width:182px"><p>Number of Patients</p></td><td style="vertical-align:top; width:215px"><p>56</p></td><td style="vertical-align:top; width:199px"><p>25</p></td></tr><tr><td style="vertical-align:top; width:182px"><p>Overall Favorable Response</p></td><td style="vertical-align:top; width:215px"><p>26/56 (46.4%)</p></td><td style="vertical-align:top; width:199px"><p>8/25(32.0%)</p></td></tr><tr><td style="vertical-align:top; width:182px"><p>High risk</p></td><td style="vertical-align:top; width:215px"><p>9/15 (60.0%)</p></td><td style="vertical-align:top; width:199px"><p>0/7 (0.0%)</p></td></tr><tr><td style="vertical-align:top; width:182px"><p>Low risk</p></td><td style="vertical-align:top; width:215px"><p>17/41 (41.5%)</p></td><td style="vertical-align:top; width:199px"><p>8/18 (44.4%)</p></td></tr></tbody></table><p><sup>*</sup>One patient excluded from analysis due to no fever at study entry.</p><p>The second study was a prospective, open-label, non-comparative study estimating the safety and efficacy of caspofungin in pediatric patients (ages 3 months to 17 years) with candidemia and other <em>Candida </em>infections, esophageal candidiasis, and invasive aspergillosis (as salvage therapy). The study employed diagnostic criteria which were based on established EORTC/MSG criteria of proven or probable infection; these criteria were similar to those criteria employed in the adult studies for these various indications. Similarly, the efficacy time points and endpoints used in this study were similar to those employed in the corresponding adult studies. All patients received Caspofungin acetate for Injection at 50 mg/m IV once daily following a 70-mg/m loading dose on Day 1 (not to exceed 70 mg daily). Among the 49 enrolled patients who received Caspofungin acetate for Injection, 48 were included in the efficacy analysis (one patient excluded due to not having a baseline <em>Aspergillus </em>or <em>Candida </em>infection). Of these 48 patients, 37 had candidemia or other <em>Candida </em>infections, 10 had invasive aspergillosis, and 1 patient had esophageal candidiasis. Most candidemia and other <em>Candida </em>infections were caused by <em>C. albicans </em>(35%), followed by <em>C. parapsilosis </em>(22%), <em>C. tropicalis </em>(14%), and <em>C. glabrata </em>(11%). The favorable response rate, by indication, at the end</p><p>&nbsp;</p><p>of caspofungin therapy was as follows: 30/37 (81%) in candidemia or other <em>Candida</em></p><p>infections, 5/10 (50%) in invasive aspergillosis, and 1/1 in esophageal candidiasis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Distribution</u></p><p>Plasma concentrations of caspofungin decline in a polyphasic manner following single 1 hour IV infusions. A short &alpha;-phase occurs immediately post infusion, followed by a &beta;-phase (half- life of 9 to 11 hours) that characterizes much of the profile and exhibits clear log-linear behavior from 6 to 48 hours postdose during which the plasma concentration decreases 10- fold. An additional, longer half-life phase, &gamma;-phase, (half-life of 40-50 hours), also occurs. Distribution, rather than excretion or biotransformation, is the dominant mechanism influencing plasma clearance. Caspofungin is extensively bound to albumin (~97%), and distribution into red blood cells is minimal. Mass balance results showed that approximately 92% of the administered radioactivity was distributed to tissues by 36 to 48 hours after a single 70-mg dose of [<sup>3</sup>H] Caspofungin acetate for Injection. There is little excretion or biotransformation of caspofungin during the first 30 hours after administration.</p><p><u>Metabolism</u></p><p>Caspofungin is slowly metabolized by hydrolysis and N-acetylation. Caspofungin also undergoes spontaneous chemical degradation to an open-ring peptide compound, L-747969. At later time points (&ge;5 days postdose), there is a low level (&le;7 picomoles/mg protein, or &le;1.3% of administered dose) of covalent binding of radiolabel in plasma following single-dose administration of [<sup>3</sup>H] Caspofungin acetate for Injection, which may be due to two reactive intermediates formed during the chemical degradation of caspofungin to L-747969. Additional metabolism involves hydrolysis into constitutive amino acids and their degradates, including dihydroxyhomotyrosine and N-acetyl-dihydroxyhomotyrosine. These two tyrosine derivatives are found only in urine, suggesting rapid clearance of these derivatives by the kidneys.</p><p><u>Excretion</u></p><p>Two single-dose radiolabeled pharmacokinetic studies were conducted. In one study, plasma, urine, and feces were collected over 27 days, and in the second study plasma was collected over 6 months. Plasma concentrations of radioactivity and of caspofungin were similar during the first 24 to 48 hours postdose; thereafter drug levels fell more rapidly. In plasma, caspofungin concentrations fell below the limit of quantitation after 6 to 8 days postdose, while</p><p>&nbsp;</p><p>radiolabel fell below the limit of quantitation at 22.3 weeks postdose. After single intravenous administration of [<sup>3</sup>H] Caspofungin acetate for Injection, excretion of caspofungin and its metabolites in humans was 35% of dose in feces and 41% of dose in urine. A small amount of caspofungin is excreted unchanged in urine (~1.4% of dose). Renal clearance of parent drug is low (~0.15 mL/min) and total clearance of caspofungin is 12 mL/min.</p><p>&nbsp;</p><p>Special Populations</p><p><u>Renal Impairment</u></p><p>In a clinical study of single 70-mg doses, caspofungin pharmacokinetics were similar in healthy adult volunteers with mild renal impairment (creatinine clearance 50 to 80 mL/min) and control subjects. Moderate (creatinine clearance 31 to 49 mL/min), severe (creatinine clearance 5 to 30 mL/min), and end-stage (creatinine clearance less than 10 mL/min and dialysis dependent) renal impairment moderately increased caspofungin plasma concentrations after single-dose administration (range: 30 to 49% for AUC). However, in adult patients with invasive aspergillosis, candidemia, or other <em>Candida </em>infections (intra-abdominal abscesses, peritonitis, or pleural space infections) who received multiple daily doses of Caspofungin acetate for Injection 50 mg, there was no significant effect of mild to end-stage renal impairment on caspofungin concentrations. No dosage adjustment is necessary for patients with renal impairment. Caspofungin is not dialyzable, thus supplementary dosing is not required following hemodialysis.</p><p><u>Hepatic Impairment</u></p><p>Plasma concentrations of caspofungin after a single 70-mg dose in adult patients with mild hepatic impairment (Child-Pugh score 5 to 6) were increased by approximately 55% in AUC compared to healthy control subjects. In a 14-day multiple-dose study (70 mg on Day 1 followed by 50 mg daily thereafter), plasma concentrations in adult patients with mild hepatic impairment were increased modestly (19 to 25% in AUC) on Days 7 and 14 relative to healthy control subjects. No dosage adjustment is recommended for patients with mild hepatic impairment.</p><p>Adult patients with moderate hepatic impairment (Child-Pugh score 7 to 9) who received a single 70-mg dose of Caspofungin acetate for Injection had an average plasma caspofungin increase of 76% in AUC compared to control subjects. A dosage reduction is recommended</p><p>&nbsp;</p><p>for adult patients with moderate hepatic impairment based upon these pharmacokinetic data. (see section 4.2).</p><p>There is no clinical experience in adult patients with severe hepatic impairment (Child-Pugh score greater than 9) or in pediatric patients with any degree of hepatic impairment.</p><p><u>Gender</u></p><p>Plasma concentrations of caspofungin in healthy adult men and women were similar following a single 70-mg dose. After 13 daily 50-mg doses, caspofungin plasma concentrations in women were elevated slightly (approximately 22% in area under the curve [AUC]) relative to men. No dosage adjustment is necessary based on gender.</p><p><u>Race</u></p><p>Regression analyses of patient pharmacokinetic data indicated that no clinically significant differences in the pharmacokinetics of caspofungin were seen among Caucasians, Blacks, and Hispanics. No dosage adjustment is necessary on the basis of race.</p><p><u>Geriatric Patients</u></p><p>Plasma concentrations of caspofungin in healthy older men and women (65 years of age and older) were increased slightly (approximately 28% AUC) compared to young healthy men after a single 70-mg dose of caspofungin. In patients who were treated empirically or who had candidemia or other <em>Candida </em>infections (intra-abdominal abscesses, peritonitis, or pleural space infections), a similar modest effect of age was seen in older patients relative to younger patients. No dosage adjustment is necessary for the elderly.</p><p>&nbsp;</p><p><u>Pediatric Patients</u></p><p>Caspofungin acetate for Injection has been studied in five prospective studies involving pediatric patients under 18 years of age, including three pediatric pharmacokinetic studies [initial study in adolescents (12-17 years of age) and children (2-11 years of age) followed by a study in younger patients (3-23 months of age) and then followed by a study in neonates and infants (less than 3 months of age)].</p><p>Pharmacokinetic parameters following multiple doses of Caspofungin acetate for Injection in pediatric and adult patients are presented in Table 16.</p><p>&nbsp;</p><p>Table 16: Pharmacokinetic Parameters Following Multiple Doses of Caspofungin acetate for Injection in Pediatric (3 months to 17 years) and Adult Patients</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Population</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Daily </strong><strong>Dose</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Pharmacokinetic Parameters (Mean &plusmn; Standard Deviation)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>AUC</strong><strong>0-</strong><strong>24hr</strong></p><p><strong>(&micro;g.hr/ml)</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>1hr</strong><strong> </strong><strong>(&micro;g/ml)</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>24hr</strong><strong> </strong><strong>(&micro;g/ml)</strong></p></td><td style="vertical-align:top"><p><strong>t</strong><strong>1/2</strong><strong> </strong><strong>(hr)*</strong></p></td><td style="vertical-align:top"><p><strong>CI</strong></p><p><strong>(mL/min)</strong></p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>PEDIATRIC PATIENTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Adolescents, Aged 12-17 years</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>50</p><p>mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>124.9 &plusmn; 50.4</p></td><td style="vertical-align:top"><p>14.0 &plusmn; 6.9</p></td><td style="vertical-align:top"><p>2.4 &plusmn; 1.0</p></td><td style="vertical-align:top"><p>11.2 &plusmn; 1.7</p></td><td style="vertical-align:top"><p>12.6 &plusmn; 5.5</p></td></tr><tr><td style="vertical-align:top"><p>Children, Aged 2-11 years</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>50</p><p>mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>120.0 &plusmn; 33.4</p></td><td style="vertical-align:top"><p>16.1 &plusmn; 4.2</p></td><td style="vertical-align:top"><p>1.7 &plusmn; 0.8</p></td><td style="vertical-align:top"><p>8.2 &plusmn; 2.4</p></td><td style="vertical-align:top"><p>6.4 &plusmn; 2.6</p></td></tr><tr><td style="vertical-align:top"><p>Young Children,</p><p>Aged 3-23 months</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>50</p><p>mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>131.2 &plusmn;</p><p>17.7</p></td><td style="vertical-align:top"><p>17.6 &plusmn;</p><p>3.9</p></td><td style="vertical-align:top"><p>1.7 &plusmn; 0.7</p></td><td style="vertical-align:top"><p>8.8 &plusmn;</p><p>2.1</p></td><td style="vertical-align:top"><p>3.2 &plusmn; 0.4</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>ADULT PATIENTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Adults with Esophageal Candidiasis</p></td><td style="vertical-align:top"><p>6&dagger;</p></td><td style="vertical-align:top"><p>50 mg</p></td><td style="vertical-align:top"><p>87.3 &plusmn; 30.0</p></td><td style="vertical-align:top"><p>8.7 &plusmn; 2.1</p></td><td style="vertical-align:top"><p>1.7 &plusmn; 0.7</p></td><td style="vertical-align:top"><p>13.0 &plusmn; 1.9</p></td><td style="vertical-align:top"><p>10.6 &plusmn; 3.8</p></td></tr><tr><td style="vertical-align:top"><p>Adults receiving</p><p>Empirical Therapy</p></td><td style="vertical-align:top"><p>119<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>50 mg<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>8.0 &plusmn; 3.4</p></td><td style="vertical-align:top"><p>1.6 &plusmn; 0.7</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr></tbody></table><p>*Harmonic Mean &plusmn; jackknife standard deviation</p><p>&dagger; N=5 for C<sub>1hr</sub> and AUC<sub>0-24hr</sub>; N=6 for C<sub>24hr</sub></p><p>&Dagger;N=117 for C<sub>24hr</sub>; N=119 for C<sub>1hr</sub></p><p><sup>&sect;</sup>Following an initial 70-mg loading dose on day 1</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Carcinogenesis, Mutagenesis, Impairment of Fertility</u></strong></p><p>No long-term studies in animals have been performed to evaluate the carcinogenic potential of caspofungin.</p><p>Caspofungin did not show evidence of mutagenic or genotoxic potential when evaluated in the following <em>in vitro </em>assays: bacterial (Ames) and mammalian cell (V79 Chinese hamster lung fibroblasts) mutagenesis assays, the alkaline elution/rat hepatocyte DNA strand break test, and the chromosome aberration assay in Chinese hamster ovary cells. Caspofungin was not genotoxic when assessed in the mouse bone marrow chromosomal test at doses up to 12.5 mg/kg (equivalent to a human dose of 1 mg/kg based on body surface area comparisons), administered intravenously.</p><p>Fertility and reproductive performance were not affected by the intravenous administration of caspofungin to rats at doses up to 5 mg/kg. At 5 mg/kg exposures were similar to those seen in patients treated with the 70-mg dose.</p><p><strong><u>Animal Toxicology and/or Pharmacology</u></strong></p><p>In one 5-week study in monkeys at doses which produced exposures approximately 4 to 6 times those seen in adult patients treated with a 70-mg dose, scattered small foci of subcapsular necrosis were observed microscopically in the livers of some animals (2/8 monkeys at 5 mg/kg and 4/8 monkeys at 8 mg/kg); however, this histopathological finding was not seen in another study of 27 weeks duration at similar doses.</p><p>No treatment-related findings were seen in a 5-week study in infant monkeys at doses which produced exposures approximately 3 times those achieved in pediatric patients receiving a maintenance dose of 50 mg/m daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol<br />Sucrose<br />Glacial acetic acid<br />Sodium Hydroxide (to adjust the pH)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not mix or co-infuse Caspofungin acetate for Injection with other medications, as there are no data available on the compatibility of Caspofungin acetate for Injection with other intravenous substances, additives, or medications.<br />Do not use diluents containing dextrose (&alpha;-D-glucose), as Caspofungin acetate for Injection is not stable in diluents containing dextrose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store Refrigerated at 2&deg;C &ndash; 8&deg;C (36 &deg;F&ndash; 46 &deg;F).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The container closure system for Caspofungin acetate for Injection is listed below. <u>Caspofungin acetate for Injection, 50 mg/vial, 10 mL clear glass tubular Lyo vial</u></p><p>10 mL USP Type-I clear glass tubular Lyo vials with 20 mm ready to sterilize bromobutyl double slotted Lyo rubber stoppers and 20 mm aluminum flip-off seals with button.</p><p>&nbsp;</p><p><u>Caspofungin acetate for Injection, 70 mg/vial, 10 mL clear glass tubular Lyo vial</u></p><p>10 mL USP Type-I clear glass tubular Lyo vials with 20 mm ready to sterilize bromobutyl double slotted Lyo rubber stoppers and 20 mm aluminum flip-off seals with button.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preparation for Administration</p><p><em><u>Reconstitution of Caspofungin acetate for Injection for Intravenous Infusion</u></em></p><p>A.&nbsp;&nbsp; Equilibrate the refrigerated vial of Caspofungin acetate for Injection to room temperature.</p><p>B.&nbsp;&nbsp;&nbsp; Aseptically add 10.8 mL of 0.9% Sodium Chloride Injection, Sterile Water for Injection, Bacteriostatic Water for Injection with methylparaben and propylparaben, or Bacteriostatic Water for Injection with 0.9% benzyl alcohol to the vial.</p><p>C.&nbsp;&nbsp;&nbsp; Each vial of Caspofungin acetate for Injection contains an intentional overfill of Caspofungin acetate for Injection. Thus, the volume of diluent to be added to each vial and the drug concentration of the resulting solution is listed in Table 17 below.</p><p>Table 17: Information for Preparation of Caspofungin acetate for Injection</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Caspofungin acetate for Injection</strong></p><p><strong>vial (equivalent to caspofungin)</strong></p></td><td style="vertical-align:top"><p><strong>Volume of diluent</strong></p><p><strong>to be added*</strong></p></td><td style="vertical-align:top"><p><strong>Resulting Concentration</strong></p><p><strong>following Reconstitution</strong></p></td></tr><tr><td style="vertical-align:top"><p>50 mg</p></td><td style="vertical-align:top"><p>10.8 mL</p></td><td style="vertical-align:top"><p>5 mg/mL</p></td></tr><tr><td style="vertical-align:top"><p>70 mg</p></td><td style="vertical-align:top"><p>10.8 mL</p></td><td style="vertical-align:top"><p>7 mg/mL</p></td></tr></tbody></table><p>*Reconstitution volume of diluent to be added is based on the overfill amount of caspofungin (54 .6 mg and 75.6 mg, respectively).</p><p>D.&nbsp; The white to off-white cake will dissolve completely. Mix gently until a clear solution is obtained. Visually inspect the reconstituted solution for particulate matter or discoloration during reconstitution and prior to infusion. Do not use if the solution is cloudy or has precipitated.</p><p>E.&nbsp; The reconstituted solution of Caspofungin acetate for Injection in the vial may be stored for up to one hour at &le;25&deg;C (&le;77&deg;F) prior to the preparation of the infusion solution in the intravenous bag or bottle.</p><p>F.&nbsp; Caspofungin acetate for Injection vials are for single-dose only. Discard unused portion.</p><p><em><u>Dilution of the Reconstituted Solution in the Intravenous Bag for Infusion</u></em></p><p>A.&nbsp; Aseptically transfer the appropriate volume (mL) of reconstituted Caspofungin acetate for Injection to an intravenous (IV) bag (or bottle) containing 250 mL of 0.9%, 0.45%, or</p><p>&nbsp;</p><p>0.225% Sodium Chloride Injection or Lactated Ringers Injection.</p><p>B.&nbsp; Alternatively, the volume (mL) of reconstituted Caspofungin acetate for Injection can be added to a reduced volume of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection or Lactated Ringers Injection, not to exceed a final concentration of 0.5 mg/mL.</p><p>C.&nbsp; This diluted infusion solution in the intravenous bag or bottle must be used within 24 hours if stored at &le;25&deg;C (&le;77&deg;F) or within 48 hours if stored refrigerated at 2 to 8&deg;C (36 to 46&deg;F).</p><p>Important Reconstitution and Dilution Instructions for Pediatric Patients 3 Months of Age and Older</p><p>Follow the reconstitution procedures described above using either the 70-mg or 50-mg vial to create the reconstituted solution (see section 4.2). From the reconstituted solution in the vial, remove the volume of drug equal to the calculated loading dose or calculated maintenance dose based on a concentration of 7 mg/mL (if reconstituted from the 70-mg vial) or a concentration of 5 mg/mL (if reconstituted from the 50-mg vial).</p><p>The choice of vial should be based on total milligram dose of drug to be administered to the pediatric patient. To help ensure accurate dosing, it is recommended for pediatric doses less than 50 mg that 50-mg vials (with a concentration of 5 mg/mL) be used if available. The 70- mg vial should be reserved for pediatric patients requiring doses greater than 50 mg.</p><p><em>The maximum loading dose and the daily maintenance dose should not exceed 70 mg, regardless of the patient&#39;s calculated dose.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical Company,
Sudair Industrial Zone,
Sudair,
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>